

=> b reg  
FILE 'REGISTRY' ENTERED AT 09:23:49 ON 15 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 AUG 2006 HIGHEST RN 901253-54-1  
DICTIONARY FILE UPDATES: 14 AUG 2006 HIGHEST RN 901253-54-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta l23  
L21 STR



VAR G1=O/S  
VAR G2=8/13  
VAR G3=N/AK/CY  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE  
L23 453 SEA FILE=REGISTRY SSS FUL L21

100.0% PROCESSED 1640 ITERATIONS 453 ANSWERS  
SEARCH TIME: 00.00.01

=> b hcap  
FILE 'HCAPLUS' ENTERED AT 09:23:56 ON 15 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Aug 2006 VOL 145 ISS 8  
FILE LAST UPDATED: 14 Aug 2006 (20060814/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs fhitstr hitrn l26 tot

|         |  |   |                           |                 |              |
|---------|--|---|---------------------------|-----------------|--------------|
| L26     | ANSWER 1 OF 2  | HCAPLUS   | COPYRIGHT 2006 ACS on STN |                 |              |
| AN      | 2004:589549  | HCAPLUS   |                           |                 |              |
| DN      | 141:140450   |   |                           |                 |              |
| TI      | Preparation of 2-oxopyridin-3-yl thia(di)azoles as Cdk2 and Cdk5 kinase inhibitors for the treatment of cell proliferation-related disorders |   |                           |                 |              |
| IN      | Zhong, Wenge; Norman, Mark Henry; Kaller, Matthew; Nguyen, Thomas; Rzasa, Robert Michael; Tegley, Christopher; Wang, Hui-Ling                |   |                           |                 |              |
| PA      | Amgen Inc., USA  |   |                           |                 |              |
| SO      | PCT Int. Appl., 317 pp.<br>CODEN: PIXXD2   |   |                           |                 |              |
| DT      | Patent   |   |                           |                 |              |
| LA      | English  |   |                           |                 |              |
| FAN.CNT | 1  |   |                           |                 |              |
|         | PATENT NO.   | KIND  | DATE                      | APPLICATION NO. | DATE         |
| PI      | WO2004060890   | A1  | 20040722                  | 2003WO-US41388  | 20031222 <-- |
|         | WO2004060890   | C1  | 20050818                  |                 |              |
|         | W:   | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,<br>CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,<br>GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,<br>LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,<br>OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,<br>TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW |                           |                 |              |
|         | RW:  | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,<br>BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,<br>ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,<br>TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |                           |                 |              |
|         | US2004147561   | A1  | 20040729                  | 2003US-0736289  | 20031212 <-- |
|         | CA---2509213   | AA  | 20040722                  | 2003CA-2509213  | 20031222 <-- |
|         | AU2003299980   | A1  | 20040729                  | 2003AU-0299980  | 20031222 <-- |
|         | EP---1575947   | A1  | 20050921                  | 2003EP-0800245  | 20031222 <-- |
|         | R:   | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |                           |                 |              |
|         | JP2006514059   | T2  | 20060427                  | 2004JP-0565746  | 20031222 <-- |
| PRAI    | 2002US-436787P   | P   | 20021227                  | <--             |              |
|         | 2003US-0736289   | A   | 20031212                  | <--             |              |
|         | 2003WO-US41388   | W   | 20031222                  | <--             |              |
| OS      | MARPAT   | 141:140450  |                           |                 |              |
| GI      |  |   |                           |                 |              |


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein A = O or S; Q = NH<sub>2</sub> and derivs., NHC(:O)H, alkyl-OH and derivs., (un)substituted monocyclic or bicyclic, etc; W = (un)substituted 1,3-thiazolyl, 1,2,4-thiadiazolyl; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> =


independently H, halo, aryl, alk(en/yn)yl, perfluoroalkyl, NO<sub>2</sub>, heterocyclyl, NH<sub>2</sub> and derivs., etc.; R1CCR2 or R2CCR3 = 5-10 membered (un)saturated carbocyclic or heterocyclic and derivs.; with provisos; and pharmaceutically acceptable salts thereof] are disclosed as serine/threonine kinase inhibitors for effective treatment of cell proliferation or apoptosis-mediated diseases (no data). The invention encompasses I and pharmaceutically acceptable derivs. thereof, pharmaceutical compns., and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer, and the like (no data). For example, II was prepared by cyclization of bromoacetylpyridinone (III) (preparation given) with 2-(2-thienylsulfonyl)ethanethioamide in EtOH under microwave conditions at 150° for 5 min. II exhibited Cdk2/cyclin and Cdk5/p25 kinase activity with IC<sub>50</sub> values < 0.5 μM and inhibited cell proliferation of human PC-3 prostate cells, HCT 116 human colon carcinoma cells, or HT 29 human colon carcinoma cells with IC<sub>50</sub> < 1 μM.

- IT 727383-80-4P, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid trifluoroacetate  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
 (Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)
- RN 727383-80-4 HCPLUS
- CN 3-Pyridinecarboxylic acid, 1,6-dihydro-2-methyl-6-oxo-5-[2-(4-pyridinyl)-4-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 727383-79-1  
 CMF C15 H11 N3 O3 S

CM 2

CRN 76-05-1  
 CMF C2 H F3 O2

- IT 727383-80-4P, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid trifluoroacetate  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
 (Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

- IT 727382-46-9P, Ethyl 2-ethyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydropyridine 3-carboxylate 727382-58-3P, Ethyl 2-isopropyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-61-8P, Ethyl 2-isopropyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-78-7P 727383-04-2P, Ethyl 5-[2-(2-chloro-4-pyridinyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-27-9P, Ethyl 5-[2-(4-Methoxybenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-30-4P, Ethyl 2-methyl-5-[2-(methylamino)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-52-0P, 2-(Isopropyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylic acid 727383-77-9P, 1,1-Dimethylethyl 2-methyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-89-3P, 5-Hydroxymethyl-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-52-3P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-hydroxyethyl)amide 727384-54-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-hydroxypropyl)amide 727384-61-4P, 2-(2-Benzylxyethyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester 727384-65-8P, 2-(2-Hydroxyethyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)
- IT 727382-48-1P 727382-49-2P, Ethyl 2-ethyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-50-5P, Ethyl 2-ethyl-6-oxo-5-[2-(benzodioxol-5-yl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-51-6P, Ethyl 6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate 727382-53-8P, Ethyl 2-trifluoromethyl-6-oxo-5-[2-(3-chloro-4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-55-0P, Ethyl 6-oxo-5-[2-[(2-pyridylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate 727382-56-1P, Ethyl 6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate 727382-57-2P, Ethyl 2-trifluoromethyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-60-7P, Ethyl 2-isopropyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-62-9P, Ethyl 2-propyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-65-2P, Ethyl 2-propyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-66-3P, Ethyl 2-propyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-67-4P, Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-71-0P, Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-72-1P, Ethyl 6-oxo-2-[(4-pyridin-4-yl)-1,3-thiazol-4-yl]-1,7,8-trihydro-5H-pyrano[4,3-b]pyridin-2-one 727382-76-5P 727382-79-8P, 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]-1,5,6,7,8-pentahydropyridino[3,2-c]pyridin-2-one dihydrochloride 727382-80-1P, Ethyl 2-[[[(4-methoxyphenyl)methoxy]methyl]-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-85-6P, Ethyl 2-methyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-89-0P, Ethyl 5-[2-[[[(4-fluorophenyl)methyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727382-90-3P, Ethyl 2-methyl-6-oxo-5-[2-(2-thienyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-

pyridinecarboxylate 727382-92-5P, Ethyl 2-methyl-6-oxo-5-[2-(phenylthiomethyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727382-93-6P, Ethyl 5-[2-(2-ethyl-4-pyridinyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727382-94-7P,  
 Ethyl 2-methyl-6-oxo-5-[2-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]methoxy]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727382-95-8P, Ethyl 2-methyl-6-oxo-5-[2-(3-thienyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-96-9P, Ethyl  
 5-[2-(2H-benzo[d]-1,3-dioxolan-5-yl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727382-97-0P, Ethyl  
 2-methyl-6-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate 727382-98-1P, Ethyl 2-methyl-6-oxo-5-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727382-99-2P, Ethyl 5-[2-(2,6-dichlorophenyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-00-8P,  
 Ethyl 2-methyl-5-[2-(2-methyl-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-01-9P, Ethyl  
 5-[2-[(furan-2-ylmethyl)sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-02-0P, Ethyl  
 5-[2-[(tert-butyl)sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-03-1P, Ethyl  
 2-methyl-6-oxo-5-[2-(3-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-06-4P, Ethyl 2-methyl-6-oxo-5-[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727383-07-5P, Ethyl 5-[2-(3,5-dichloropyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-08-6P,  
 Ethyl 5-[2-[(methylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-09-7P, Ethyl  
 5-[2-[3-[(4-chlorophenyl)sulfonyl]methyl]-2-thienyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-10-0P,  
 Ethyl 2-methyl-6-oxo-5-[2-[2-(1-piperidinyl)-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-11-1P, Ethyl  
 2-methyl-5-[2-[2-[(2-methylpropyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-12-2P, Ethyl  
 2-methyl-6-oxo-5-[2-[2-[(3-pyridinylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-13-3P, Ethyl  
 2-methyl-6-oxo-5-[2-[2-[(phenylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-14-4P, Ethyl  
 2-methyl-6-oxo-5-[2-[2-[2-oxo-3-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-15-5P  
 , Ethyl 5-[2-[2-[(2-diethylamino)ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-16-6P  
 , Ethyl 5-[2-[2-[(fur-2-ylmethyl)aminopyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-17-7P  
 , Ethyl 5-[2-[2-[(thien-2-yl)ethyl]amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride  
 727383-18-8P, Ethyl 5-[2-[2-(4-fluorobenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate  
 hydrochloride 727383-19-9P, Ethyl 5-[2-(2-butylaminopyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate  
 hydrochloride 727383-20-2P, Ethyl 5-[2-[(carbamoylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-21-3P, Ethyl  
 5-[2-[2-[2-(acetylamino)ethylamino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride  
 727383-22-4P, N-[2-[(4-[4-(6-Methyl-2-oxo-1,2-dihydropyridin-3-yl)-1,3-thiazol-2-yl]pyridin-2-yl)amino]ethyl]acetamide 727383-23-5P  
 , N-(Cyclopropylmethyl)-5-[2-[2-[(cyclopropylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide  
 hydrochloride 727383-24-6P, Ethyl 5-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-25-7P,  
 Ethyl 5-[2-[2-[(Cyclopentylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride  
 727383-26-8P, 5-[2-[2-[(4-Methoxybenzyl)amino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid

N-(4-methoxybenzyl)amide hydrochloride 727383-28-0P, Ethyl  
 2-methyl-6-oxo-5-[2-[2-(amino)-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-29-1P 727383-31-5P, Ethyl  
 2-methyl-5-[2-[methyl(phenylsulfonyl)amino]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-32-6P 727383-33-7P,  
 , Ethyl 2-methyl-5-[2-[methyl(phenylsulfonyl)amino]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride (1/2)  
 727383-34-8P, 5-[(Phenylmethyl)oxy]-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-35-9P, 6-(Methoxymethyl)-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-37-1P,  
 5-Phenoxy-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-38-2P, 5-Phenoxy-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone hydrochloride (1/3) 727383-39-3P,  
 6-Methyl-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-40-6P, Ethyl 2-(1-methylethyl)-5-[2-(2-methoxy-4-pyridinyl)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-42-8P, Ethyl 2-methyl-5-[2-[2-(methoxy)-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-43-9P,  
 , Ethyl 2-methyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-44-0P, Ethyl  
 2-methyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-45-1P, Ethyl 2-methyl-6-oxo-5-[2-[(2-pyridylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-46-2P, Ethyl 2-methyl-5-[2-[1-methyl-1-(phenylsulfonyl)ethyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-47-3P, Ethyl 2-cyclopropyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-51-9P, Ethyl 2-cyclopropyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-53-1P, 5-Bromo-6-methyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-56-4P,  
 Ethyl 2-methyl-5-[2-[2-(methylamino)-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-58-6P,  
 5-Amino-6-ethyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-65-5P, N-[2-Ethyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridin-3-yl]acetamide 727383-66-6P,  
 4-Dimethylamino-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-68-8P, 6-Methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one 727383-69-9P,  
 2-Methyl-6-oxo-N-(2-pyridinylmethyl)-5-[2-[2-[(2-pyridinyl)methyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxamide 727383-70-2P, 6-Methyl-3-[2-[2-[(2-pyridinyl)methyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-71-3P,  
 Ethyl 2-methyl-6-oxo-5-[2-[2-[(2-pyridinyl)methyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-72-4P,  
 Ethyl 2-methyl-6-oxo-5-[2-[2-[(phenyloxy)ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-73-5P,  
 5-[2-[2-(Ethoxy)-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 727383-75-7P, Ethyl  
 5-[2-(2-dimethylaminopyridin-4-yl)-1,3-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-76-8P, Ethyl  
 5-[2-(2-methylaminopyridin-4-yl)-1,3-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-79-1P,  
 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 727383-81-5P, 6-Methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-82-6P, 2-(Pyrrolidin-1-yl)ethyl  
 2-methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylate 727383-84-8P, 2-(Pyrrolidin-1-yl)ethyl  
 2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylate 727383-85-9P, 6-Ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-86-0P,  
 6-Isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-87-1P, 3-(Diethylamino)propyl 2-ethyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-88-2P, 3-(Diethylamino)propyl 2-(1-methylethyl)-6-oxo-5-[2-

(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727383-91-7P, 5-[(3,6-Dihydro-2H-pyridin-1-yl)methyl]-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-94-0P  
 , 6-Ethyl-5-[(piperidin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one hydrochloride 727383-96-2P,  
 6-Ethyl-5-(4-methylpiperazin-1-ylmethyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one hydrochloride 727383-98-4P,  
 6-Ethyl-5-isobutylamino-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-01-2P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridin-3-yl]isobutyramide 727384-03-4P  
 , 6-Isopropyl-5-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-06-7P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-6-isopropyl-5-methyl-1H-pyridin-2-one 727384-08-9P,  
 6-Ethyl-5-propionyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-10-3P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-6-ethyl-5-propionyl-1H-pyridin-2-one 727384-11-4P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid  
 2-dimethylaminoethyl ester 727384-13-6P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid  
 2-(pyrrolidin-1-yl)ethyl ester 727384-14-7P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(2-oxopyrrolidin-1-yl)ethyl ester  
 727384-15-8P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-diisopropylaminoethyl ester  
 727384-16-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-diethylaminoethyl ester  
 727384-17-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 1-methylpyrrolidin-3-yl ester  
 727384-18-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 1-ethylpyrrolidin-3-yl ester  
 727384-19-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 1-ethylpiperidin-3-yl ester  
 727384-20-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid piperidin-4-ylmethyl ester  
 727384-22-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(1-methylpyrrolidin-2-yl)ethyl ester  
 727384-23-8P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 1-methylpiperidin-3-yl ester  
 727384-24-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-dimethylamino-1-methylethyl ester 727384-25-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid  
 2-diethylamino-1-methylethyl ester 727384-26-1P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-[(benzyl)(methyl)amino]ethyl ester  
 727384-27-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 1-methylpiperidin-4-yl ester  
 727384-28-3P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(piperazin-1-yl)ethyl ester  
 727384-29-4P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(2-oxopyrrolidin-1-yl)propyl ester  
 727384-30-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid phenethyl ester  
 727384-32-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(thiophen-2-yl)ethyl ester  
 727384-33-0P, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihdropyridine-3-carboxylic acid 2-diethylaminoethyl ester  
 727384-36-3P, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihdropyridine-3-carboxylic acid 2-diethylamino-1-methylethyl ester 727384-37-4P, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihdropyridine-3-carboxylic acid 2-diethylaminopropyl ester 727384-38-5P,  
 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihdropyridine-3-carboxylic acid 2-(1-methylpyrrolidin-2-yl)ethyl ester  
 727384-39-6P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(morpholin-4-yl)ethyl ester

727384-40-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(piperidin-1-yl)ethyl ester  
 727384-41-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid methyl ester  
 727384-42-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid methyl ester trifluoroacetate  
 727384-43-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid propyl ester  
 727384-44-3P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid propyl ester trifluoroacetate  
 727384-45-4P  
 , 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid butyl ester 727384-46-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid butyl ester trifluoroacetate 727384-47-6P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid isobutyl ester 727384-48-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid isobutyl ester trifluoroacetate 727384-49-8P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid sec-butyl ester 727384-50-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid sec-butyl ester trifluoroacetate 727384-55-6P, 5-(4,5-Dihydrooxazol-2-yl)-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one  
 727384-56-7P, 6-Isopropyl-5-(5-methyl-4,5-dihydrooxazol-2-yl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-57-8P,  
 5-[(2-Dimethylaminoethyl)(ethyl)amino]methyl]-6-ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-59-0P,  
 5-[(2-Diethylaminoethyl)(methyl)amino]methyl]-6-ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-66-9P,  
 6-Oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-2-[2-(pyrrolidin-1-yl)ethyl]-1,6-dihdropyridine-3-carboxylic acid ethyl ester 727384-68-1P,  
 2-Isopropyl-N-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxamide 727384-69-2P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid amide 727384-70-5P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid isobutylamide 727384-72-7P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid methylamide 727384-73-8P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid (2-isopropylaminoethyl)amide  
 727384-74-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid dimethylamide  
 727384-75-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid N-(pyridin-4-ylmethyl)amide  
 727384-76-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid N-(pyridin-2-ylmethyl)amide  
 727384-78-3P, 5-(Furan-2-yl)-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-83-0P,  
 N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-2-methylaminoacetamide 727384-84-1P, 2-Dimethylamino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]acetamide 727384-85-2P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-3-(piperidin-1-yl)propionamide  
 727384-86-3P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-3-methylbutyramide 727384-87-4P,  
 2-Amino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]acetamide 727384-88-5P, 2-tert-Butylamino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]acetamide 727384-89-6P, (S)-2-Amino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-3-methylbutyramide 727384-90-9P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-2-(piperidin-1-yl)acetamide  
 727384-92-1P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-4-(piperidin-1-yl)butyramide

727384-93-2P, 5-(1,1-Dioxidoisothiazolidin-2-yl)-6-ethyl-3-[2-(4-Pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727384-94-3P,  
 6-Ethyl-5-(3-methylbutylamino)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-95-4P, Ethyl 5-[2-[2-[(fur-2-ylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727384-96-5P, Ethyl  
 5-[2-[2-[(2-(thien-2-yl)ethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727384-97-6P, Ethyl  
 5-[2-(2-butylaminopyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727384-98-7P, Ethyl  
 5-[2-[2-[(carbamoylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727384-99-8P, Ethyl  
 5-[2-(2-acetylaminooethylamino)pyridin-4-yl-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727385-00-4P,  
 5-[2-[2-[(Cyclopropylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(cyclopropylmethyl)amide  
 727385-02-6P, Ethyl 5-[2-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate  
 727385-03-7P, Ethyl 5-[2-[2-[(Cyclopentylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate  
 727385-04-8P, 5-[2-[2-(4-Methoxybenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid  
 4-methoxybenzylamide 727385-06-0P, Ethyl 5-[2-(2-methoxybenzylamino)pyridin-4-yl]thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727385-07-1P, Ethyl  
 2-methyl-5-[2-[2-[(1-methylethyl)amino]ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydropyridine-3-carboxylate 727385-08-2P  
 , Ethyl 2-isopropyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate hydrobromide (3/5)  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

IT 727383-61-1P, Ethyl 2-ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727383-62-2P, 2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylic acid  
 727383-63-3P, [2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]carbamic acid tert-butyl ester 727383-64-4P, 5-Amino-6-ethyl-1-(4-methoxybenzyl)-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1H-pyridin-2-one  
 727383-90-6P, 5-[(Imidazol-1-yl)carbonyl]-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-92-8P,  
 6-Ethyl-5-hydroxymethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-93-9P,  
 6-Ethyl-1-(4-methoxybenzyl)-5-[(piperidin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-95-1P,  
 6-Ethyl-1-(4-methoxybenzyl)-5-[(4-methylpiperazin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-00-1P,  
 6-Ethyl-5-isobutylamino-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-02-3P,  
 N-[2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridin-3-yl]isobutyramide 727384-12-5P,  
 5-[(Imidazol-1-yl)carbonyl]-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-21-6P 727384-34-1P,  
 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylic acid 727384-35-2P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-5-[(imidazol-1-yl)carbonyl]-6-isopropyl-1H-pyridin-2-one 727384-58-9P, 5-[(2-Dimethylaminoethyl)(ethyl)amino]methyl]-6-ethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-60-3P,  
 5-[(2-Diethylaminoethyl)(methyl)amino]methyl]-6-ethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

IT 727383-74-6, 5-[2-(2-Chloropyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 727384-67-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

L26 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:633706 HCAPLUS

DN 139:180057

TI Preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurological disorders and apoptosis

IN Norman, Mark; Wang, Hui-ling; Rzasa, Robert;  
 Zhong, Wenge; Nguyen, Thomas; Kaller, Matthew

PA Amgen Inc., USA

SO PCT Int. Appl., 490 pp.





CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

|      | PATENT NO.     | KIND       | DATE   | APPLICATION NO. | DATE     |
|------|----------------|------------|--|-----------------|----------|
| PI   | WO2003066630   | A2         | 20030814   | 2003WO-US03762  | 20030207 |
|      | WO2003066630   | A3         | 20031218   |                 |          |
|      |                | W:         | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW |                 |          |
|      |                | RW:        | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |                 |          |
|      | US---6822097   | B1         | 20041123   | 2003US-0360226  | 20030206 |
|      | CA---2475637   | AA         | 20030814   | 2003CA-2475637  | 20030207 |
|      | AU2003209058   | A1         | 20030902   | 2003AU-0209058  | 20030207 |
|      | EP---1478645   | A2         | 20041124   | 2003EP-0707786  | 20030207 |
|      |                | R:         | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |                 |          |
|      | JP2005526029   | T2         | 20050902   | 2003JP-0566003  | 20030207 |
| PRAI | 2002US-355313P | P          | 20020207   |                 |          |
|      | 2003US-0360226 | A1         | 20030206   |                 |          |
|      | 2003WO-US03762 | W          | 20030207   |                 |          |
| OS   | MARPAT         | 139:180057 |  |                 |          |
| GI   |                |            |  |                 |          |




**AB** The title compds. [I; Ar = II or III; A = O, S, NH; D = CR1, N; E = CR2, N; F = CR3, N; G = CR4, N; J = NR6, S, O, CR1; K = NR6, S, O, CR2; L = NR6, S, O, CR3; Q = OH, (un)substituted NH, aryl, etc.; W = (un)substituted monocyclic (non)aromatic heterocyclic ring; Z = H, (un)substituted NH2, SH, OH, etc.; R1-R4 = H, halo, aryl, etc.; R6 = H, alkyl, a lone pair electrons] and their pharmaceutically acceptable salts, useful for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like, were prepared E.g., a 4-step synthesis of IV (starting from thioisonicotinamide and Me 4-chloroacetoacetate) which showed IC50 of < 1  $\mu$ M against cdk2/cyclin kinase and against cdk5/p25, was given. A pharmaceutical composition comprising compound I was claimed.

**IT** 578017-64-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of thiazoyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

**RN** 578017-64-8 HCPLUS

**CN** 5-Quinolinecarboxylic acid, 1,2-dihydro-2-oxo-3-[2-(4-pyridinyl)-4-thiazoyl]-, methyl ester (9CI) (CA INDEX NAME)



**IT** 578017-64-8P 578017-68-2P 578017-70-6P  
578017-96-6P 578018-16-3P 578018-20-9P  
578018-25-4P 578018-29-8P 578018-34-5P  
578018-44-7P 578018-57-2P 578018-62-9P  
578018-82-3P 578018-85-6P 578018-94-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of thiazoyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

**IT** 209974-99-2P 578017-57-9P 578017-58-0P  
578017-59-1P 578017-60-4P 578017-61-5P

578017-62-6P 578017-63-7P 578017-65-9P  
578017-66-0P 578017-67-1P 578017-69-3P  
578017-71-7P 578017-72-8P 578017-73-9P  
578017-74-0P 578017-75-1P 578017-76-2P  
578017-77-3P 578017-78-4P 578017-79-5P  
578017-80-8P 578017-81-9P 578017-82-0P  
578017-83-1P 578017-84-2P 578017-85-3P  
578017-87-5P 578017-89-7P 578017-90-0P  
578017-92-2P 578017-94-4P 578017-95-5P  
578017-97-7P 578017-98-8P 578017-99-9P  
578018-00-5P 578018-01-6P 578018-02-7P  
578018-03-8P 578018-04-9P 578018-05-0P  
578018-06-1P 578018-07-2P 578018-08-3P  
578018-09-4P 578018-10-7P 578018-11-8P  
578018-12-9P 578018-13-0P 578018-14-1P  
578018-15-2P 578018-17-4P 578018-18-5P  
578018-19-6P 578018-21-0P 578018-22-1P  
578018-23-2P 578018-24-3P 578018-26-5P  
578018-27-6P 578018-28-7P 578018-30-1P  
578018-31-2P 578018-32-3P 578018-33-4P  
578018-35-6P 578018-36-7P 578018-37-8P  
578018-38-9P 578018-39-0P 578018-40-3P  
578018-41-4P 578018-42-5P 578018-43-6P  
578018-45-8P 578018-46-9P 578018-47-0P  
578018-48-1P 578018-49-2P 578018-50-5P  
578018-51-6P 578018-52-7P 578018-53-8P  
578018-54-9P 578018-55-0P 578018-56-1P  
578018-58-3P 578018-59-4P 578018-60-7P  
578018-61-8P 578018-63-0P 578018-64-1P  
578018-65-2P 578018-66-3P 578018-67-4P  
578018-68-5P 578018-69-6P 578018-76-5P  
578018-77-6P 578018-78-7P 578018-79-8P  
578018-80-1P 578018-81-2P 578018-83-4P  
578018-84-5P 578018-86-7P 578018-87-8P  
578018-88-9P 578018-89-0P 578018-90-3P  
578018-91-4P 578018-92-5P 578018-93-6P  
578018-95-8P 578018-96-9P 578018-97-0P  
578018-98-1P 578018-99-2P 578019-00-8P  
578019-01-9P 578019-02-0P 578019-03-1P  
578019-04-2P 578019-05-3P 578019-06-4P  
578019-07-5P 578019-08-6P 578019-09-7P  
578019-10-0P 578019-11-1P 578019-12-2P  
578019-13-3P 578019-14-4P 578019-15-5P  
578019-16-6P 578019-17-7P 578019-18-8P  
578019-19-9P 578019-20-2P 578019-21-3P  
578019-22-4P 578019-23-5P 578019-24-6P  
578019-25-7P 578019-26-8P 578019-27-9P  
578019-28-0P 578019-29-1P 578019-30-4P  
578019-31-5P 578019-32-6P 578019-33-7P  
578019-34-8P 578019-35-9P 578019-36-0P  
578019-37-1P 578019-38-2P 578019-39-3P  
578019-40-6P 578019-41-7P 578019-42-8P  
578019-43-9P 578019-44-0P 578019-45-1P  
578019-46-2P 578019-47-3P 578019-48-4P  
578019-49-5P 578019-50-8P 578019-51-9P  
578019-52-0P 578019-53-1P 578019-54-2P  
578019-55-3P 578019-56-4P 578019-57-5P  
578019-58-6P 578019-59-7P 578019-60-0P  
578020-21-0P 578020-22-1P 578020-24-3P  
578020-26-5P 578020-27-6P 578020-28-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of thiazolyl substituted quinolinones for treating cell  
proliferative disorders, neurol. disorders and apoptosis)

IT 578020-18-5 578020-20-9


RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of thiazolyl substituted quinolinones for treating cell  
 proliferative disorders, neurol. disorders and apoptosis)

IT 578020-04-9P 578020-08-3P 578020-09-4P  
 578020-11-8P 578020-12-9P 578020-13-0P  
 578020-14-1P 578020-15-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of thiazolyl substituted quinolinones for treating cell  
 proliferative disorders, neurol. disorders and apoptosis)

=> d bib abs hitstr retable 128 tot

L28 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:610450 HCAPLUS  
 DN 139:164813  
 TI Preparation of imidazo[1,2-a]pyridine derivatives as antifungal agents  
 IN Takemura, Makoto; Takahashi, Hisashi; Kawakami, Katsuhiro; Takeshita,  
 Hiroshi; Kimura, Youichi; Watanabe, Jun; Sugimoto, Yuichi; Kitamura,  
 Akihiro; Nakajima, Ryohei; Kanai, Kazuo; Fujisawa, Tetsunori  
 PA Daiichi Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 309 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

| PATENT NO.   | KIND | DATE         | APPLICATION NO. | DATE         |
|--|------|--------------|-----------------|--------------|
| PI WO2003064422  | A1   | 20030807     | 2003WO-JP00912  | 20030130 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,<br>CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,<br>GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,<br>LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,<br>PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,<br>UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |              |                 |              |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,<br>KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,<br>FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,<br>BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |              |                 |              |
| CA---2474850   | AA   | 20030807     | 2003CA-2474850  | 20030130 <-- |
| EP---1479681   | A1   | 20041124     | 2003EP-0734891  | 20030130 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |              |                 |              |
| US2005113397   | A1   | 20050526     | 2003US-0502971  | 20030130 <-- |
| CN---1633434   | A    | 20050629     | 2003CN-0806794  | 20030130 <-- |
| NO2004003211   | A    | 20041027     | 2004NO-0003211  | 20040728 <-- |
| PRAI 2002JP-0022767  | A    | 20020131 <-- |                 |              |
| 2003WO-JP00912   | W    | 20030130     |                 |              |
| 2003WO-JP00913   | A    | 20030130     |                 |              |
| OS MARPAT 139:164813   |      |              |                 |              |
| GI   |      |              |                 |              |



AB The title compds. (I), salts thereof, or solvates of either [wherein the

ring A = (un)substituted benzene ring or 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; R1 = H, halo, each (un)protected NH<sub>2</sub>, HO, or SH, NO<sub>2</sub>, cyano, CHO, CO<sub>2</sub>H, each (un)substituted CONH<sub>2</sub>, NH<sub>2</sub>, C1-10 alkyl, C1-10 alkylamino, C1-10 alkoxy, C1-10 alkylthio, C2-6 acyl, C2-7 alkoxycarbonyl, C3-10 cycloalkyl, C3-10 cycloalkylamino, C3-10 cycloalkyloxy, C3-10 cycloalkylthio, C4-10 cycloalkenyl, C4-10 cycloalkenylamino, C4-10 cycloalkenyloxy, C4-10 cycloalkenylthio, C6-10 aryl, C6-10 arylamino, or C6-10 aryloxy, etc.; R2 = H, halo, (un)protected NH<sub>2</sub> or OH, NO<sub>2</sub>, cyano, CO<sub>2</sub>H, each (un)substituted CONH<sub>2</sub>, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C1-20 alkylamino, C1-20 alkoxy, C2-18 acyl, C2-18 alkoxycarbonyl, C3-10 cycloalkyl, C5-10 cycloalkenyl, C3-10 cycloalkylamino, or C4-16 cycloalkylalkyl, etc.; R3 = H, halo, (un)protected NH<sub>2</sub>, OH, or SH, NO<sub>2</sub>, cyano, CHO, CO<sub>2</sub>H, each (un)substituted CONH<sub>2</sub>, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkylthio, C2-5 acyl, or C2-5 alkoxycarbonyl, etc.; R4 = H, halo, (un)protected NH<sub>2</sub> or OH, NO<sub>2</sub>, cyano, CO<sub>2</sub>H, SO<sub>3</sub>H, each (un)substituted CONH<sub>2</sub>, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-5 acyl, C2-5 alkoxycarbonyl, C1-6 alkylcarbonyloxy, or C1-6 alkylloxysulfonyl, etc.] are prepared. These compds. have a wide spectrum of antifungal activity by a novel mechanism, i.e., specific or selective 1,6-β-glucan synthesis inhibition. Thus, 1-chloro-3-methyl-2-phenylpyrido[1,2-a]benzimidazole-4-carbonitrile, (3S)-dimethylaminopyrrolidine, Et<sub>3</sub>N, and DMF were heated at 80° for 14 h in a sealed vessel to give 61% 1-[(3S)-dimethylpyrrolidin-1-yl]-3-methyl-2-phenylpyrido[1,2-a]benzimidazole-4-carbonitrile formate (II). II showed min. inhibitory concentration of <0.063, <0.063, and 0.5 µg/mL against *Saccharomyces cerevisiae*, *Candida glabrata*, and *C. krusei*, resp. Pharmaceutical formulations, e.g. a capsule containing 1-[2-(diethylamino)ethylamino]-2-ethyl-3-methylpyrido[1,2-a]benzimidazole-4-carbonitrile, were described.

IT 577776-44-4P 577776-48-8P 577776-51-3P


577777-06-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazo[1,2-a]pyridine derivs. as antifungal agents with specific or selective 1,6-β-glucan)


RN 577776-44-4 HCPLUS

CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 1,5-dihydro-3-methyl-2-(2-methyl-4-thiazolyl)-1-oxo- (9CI) (CA INDEX NAME)



RN 577776-48-8 HCPLUS


CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 2-(2-ethyl-4-thiazolyl)-1,5-dihydro-3-methyl-1-oxo- (9CI) (CA INDEX NAME)



RN 577776-51-3 HCPLUS


CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 1,5-dihydro-3-methyl-1-oxo-2-(2-

phenyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 577777-06-1 HCAPLUS

CN Dipyrido[1,2-a:2',3'-d]imidazole-9-carbonitrile, 1,6-dihydro-8-methyl-7-(2-methyl-4-thiazolyl)-6-oxo- (9CI) (CA INDEX NAME)



RETABLE

| Referenced Author<br>(RAU) | Year<br>(RPY) | VOL<br>(RVL) | PG<br>(RPG) | Referenced Work<br>(RWK) | Referenced<br>File |
|----------------------------|---------------|--------------|-------------|--------------------------|--------------------|
| Anon                       | 1992          | 81           | 19          | Chemico-Biological I     |                    |
| Anon                       | 2002          | 124          | 7972        | J Am Chem Soc            |                    |
| Anon                       | 1989          |              | 1895        | J Chem Soc Perkin Tr     |                    |
| Anon                       | 1995          |              | 1475        | J Chem Soc Perkin Tr     |                    |
| Anon                       | 1974          |              | 647         | J Chem Soc, Chem Com     |                    |
| Daiichi Pharm Co Ltd       | 2001          |              |             | WO---0183733 A1          | HCAPLUS            |
| Daiichi Pharm Co Ltd       | 2001          |              |             | EP---1283261 A1          | HCAPLUS            |
| Daiichi Pharm Co Ltd       | 2001          |              |             | NO2002005217 A           | HCAPLUS            |

L28 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:242331 HCAPLUS

DN 138:271542

TI Preparation of tricyclic pyridin-2-one analogues as GABAA receptor ligands

IN Bourrain, Sylvie; Crawforth, James Michael; Gibson, Karl Richard;  
Goodacre, Simon Charles; Hallett, David James; Jolley, Richard Alexander;  
Rowley, Michael; Sternfeld, Francine

PA Merck Sharp & Dohme Limited, UK

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| PATENT NO.      | KIND  | DATE     | APPLICATION NO. | DATE        |
|-----------------|---|----------|-----------------|-------------|
| PI WO2003024964 | A1  | 20030327 | 2002WO-GB03693  | 20020809 <- |
| W:              | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,<br>CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,<br>GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,<br>LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,<br>PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,<br>UG, US, UZ, VN, YU, ZA, ZM, ZW |          |                 |             |
| RW:             | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,<br>KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,<br>FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,<br>CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |             |

PRAI 2001GB-0019803  
 OS MARPAT 138:271542  
 GI

A 20010814 &lt;--



AB The title selectively substituted fused tricyclic compds. based on a substituted pyridinone moiety I [E = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; one of X, Y and Z = S and the other two of X, Y and Z = N, CH; R<sub>1</sub> = H, halo, alkyl, etc.; R<sub>2</sub> = (un)substituted (hetero)aryl; provided that, when the X,Y,Z-containing ring is thiazolyl, then R<sub>1</sub> is not Me] which are potent and functionally selective ligands for the  $\alpha$ 2/ $\alpha$ 3 subunit of the human GABA<sub>A</sub> receptor and are thereby effective in the treatment of anxiety, were prepared E.g., a 9-step synthesis of II, starting from 3-bromoisonicotinic acid, was given. The exemplified compds. I were found to possess a Ki of  $\leq$  100 nM for displacement of [<sup>3</sup>H]-flumazenil from the  $\alpha$ 2 and/or  $\alpha$ 3 subunit of the human GABA<sub>A</sub> receptor.


IT 503301-87-9P 503301-91-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic pyridin-2-one analogs as GABA<sub>A</sub> receptor ligands)


RN 503301-87-9 HCPLUS

CN Dipyrido[1,2-a:4',3'-c]azepin-9(5H)-one, 6,7-dihydro-10-(3-methyl-1,2,4-thiadiazol-5-yl)-12-phenyl- (9CI) (CA INDEX NAME)



RN 503301-91-5 HCPLUS

CN Dipyrido[1,2-a:4',3'-c]azepin-9(5H)-one, 6,7-dihydro-10-(3-methyl-1,2,4-thiadiazol-5-yl)-12-(4-pyridinyl)- (9CI) (CA INDEX NAME)



**RETABLE**

| Referenced Author<br>(RAU) | Year<br>(R PY) | VOL<br>(R VL) | PG<br>(R PG) | Referenced Work<br>(R WK) | Referenced File |
|----------------------------|----------------|---------------|--------------|---------------------------|-----------------|
| Hoffmann La Roche          | 1986           |               |              | EP--0183994 A             | HCAPLUS         |
| James, C                   | 1998           |               |              | WO--9855480 A             | HCAPLUS         |
| Metha                      | 1995           | 57            | 2215         | LIFE SCIENCES             |                 |
| Owens, A                   | 1998           |               |              | WO--9850384 A             | HCAPLUS         |

L28 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:173578 HCAPLUS

DN 138:221605

TI Preparation of tricyclic pyridin-2-one analogues as ligands for GABAA receptors

IN Bourrain, Sylvie; Goodacre, Simon Charles; Hallett, David James; Lewis, Richard Thomas; Rowley, Michael; Sternfeld, Francine; Street, Leslie Joseph

PA Merck Sharp & Dohme Limited, UK

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN, CNT 1


PATENT NO.

|    |              |   |          |                |              |
|----|--------------|---|----------|----------------|--------------|
| PI | WO2003018546 | A2  | 20030306 | 2002WO-GB03703 | 20020812 <-- |
|    | WO2003018546 | A3  | 20030717 |                |              |
|    | W:           | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,<br>CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,<br>GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,<br>LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,<br>PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,<br>UG, US, UZ, VN, YU, ZA, ZM, ZW |          |                |              |
|    | RW:          | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,<br>KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,<br>FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,<br>CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG   |          |                |              |

PRAI 2001GB-0020345 A 20010821 <--

PRAT 2001GB-0020345  
OS MRPAT 138:221605


03  
GT




**AB** The title fused tricyclic compds. I [E = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; Q = the residue of an imidazole or triazole ring; R<sub>1</sub>, R<sub>2</sub> = H, halo, heterocyclyl, etc.; R<sub>3</sub> = H, alkyl] which are potent and functionally selective ligands for the  $\alpha_2/\alpha_3$  subunit of the human GABA<sub>A</sub> receptor and are thereby effective in the treatment of anxiety and convulsions, were prepared E.g., a 7-step synthesis of II, starting from Et (4-methylthiazol-2-yl)acetate

and 3-aminopropanol, was given. The exemplified compds. I were found to possess a Ki of  $\leq$  100 nM for displacement of [<sup>3</sup>H]-flumazenil from the  $\alpha_2$  and/or  $\alpha_3$  subunit of the human GABAA receptor.

- IT 500725-52-0P 500725-59-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of tricyclic pyridin-2-one analogs as ligands for GABAA receptors)
- RN 500725-52-0 HCPLUS
- CN 5H,9H-Imidazo[1,5-a]pyrido[2,1-c][1,4]diazepin-9-one, 6,7-dihydro-10-(2-methyl-4-thiazolyl)-12-phenyl- (9CI) (CA INDEX NAME)



- RN 500725-59-7 HCPLUS
- CN 5H,9H-Imidazo[1,5-a]pyrido[2,1-c][1,4]diazepin-9-one, 6,7-dihydro-10-(3-methyl-1,2,4-thiadiazol-5-yl)-12-phenyl- (9CI) (CA INDEX NAME)





- L28 ANSWER 4 OF 10 HCPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:154431 HCPLUS  
 DN 138:205041  
 TI Preparation of tricyclic pyridin-2-one analogues as ligands for GABAA receptors  
 IN Crawforth, James Michael; Gibson, Karl Richard; Goodacre, Simon Charles; Hallett, David James; Jolley, Richard Alexander; Rowley, Michael; Sternfeld, Francine  
 PA Merck Sharp & Dohme Limited, UK  
 SO PCT Int. Appl., 71 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

|    | PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE         |
|----|---|------|----------|-----------------|--------------|
| PI | WO2003016311  | A1   | 20030227 | 2002WO-GB03705  | 20020809 <-- |
|    | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |      |          |                 |              |
|    | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |              |

PRAI 2001GB-0019828 A 20010814 <--

OS MARPAT 138:205041  
GI



AB The title selectively substituted fused tricyclic compds. based on a substituted pyridinone moiety [I; E = (CH<sub>2</sub>)<sub>n</sub>; n = 1-3; R1 = (un)substituted aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, etc.; R2 = (un)substituted aryl, heteroaryl; R3 = alkyl, hydroxyalkyl, alkenyl, etc., excluding compds. in which R1 = methylthiazolyl or hydroxymethylthiazolyl] which are potent and functionally selective ligands for the  $\alpha$ 2/ $\alpha$ 3 subunit of the human GABAA receptor and are thereby effective in the treatment of anxiety and convulsions, were prepared. Thus, reacting 1-{4-[3-(tert-butyldimethylsilyloxy)propyl]pyridin-3-yl}-3-dimethylamino-2-phenylpropanone with 2-(thien-2-yl)acetamide (preps. given) in the presence of lithium hexamethyldisilazide in THF followed by cyclization of the intermediate by treatment with triphenylphosphine in the presence of DEAD in THF afforded II. The exemplified compds. I showed Ki of  $\leq$ 100 nM for displacement of [<sup>3</sup>H]-flumazenil from the  $\alpha$ 2 and/or  $\alpha$ 3 subunit of the human GABAA receptor.


IT 500165-79-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic pyridin-2-one analogs as ligands for GABAA receptors)

RN 500165-79-7 HCAPLUS


CN Dipyrido[1,2-a:3',4'-c]azepin-9(5H)-one, 6,7-dihydro-10-(3-methyl-1,2,4-thiadiazol-5-yl)-12-phenyl- (9CI) (CA INDEX NAME)



#### RETABLE

| Referenced Author<br>(RAU) | Year<br>(R PY) | VOL<br>(R VL) | PG<br>(R PG) | Referenced Work<br>(RWK) | Referenced<br>File |
|----------------------------|----------------|---------------|--------------|--------------------------|--------------------|
| Albaugh, P                 | 1994           |               |              | US---5328912 A           | HCAPLUS            |
| Denzel, T                  | 1978           |               |              | US---4072681 A           | HCAPLUS            |
| Hoffmann La Roche          | 1986           |               |              | EP---0183994 A           | HCAPLUS            |
| Horvath                    | 1994           |               |              | WO---9425461 A           | HCAPLUS            |
| Nadin, A                   | 1999           | 40            | 4073         | TETRAHEDRON LETTERS      | HCAPLUS            |
| Neurogen Corp              | 1994           |               |              | WO---9415937 A           | HCAPLUS            |
| Owens, A                   | 1998           |               |              | WO---9850384 A           | HCAPLUS            |





L28 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:237765 HCAPLUS

DN 137:196

TI 3-Heteroaryl-2-pyridones: Benzodiazepine Site Ligands with Functional Selectivity for  $\alpha$ 2/ $\alpha$ 3-Subtypes of Human GABAA Receptor-Ion Channels

AU Collins, Ian; Moyes, Christopher; Davey, William B.; Rowley, Michael; Bromidge, Frances A.; Quirk, Kathleen; Atack, John R.; McKernan, Ruth M.; Thompson, Sally-Ann; Wafford, Keith; Dawson, Gerard R.; Pike, Andrew; Sohal, Bindu; Tsou, Nancy N.; Ball, Richard G.; Castro, Jose L.

CS Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Harlow, CM20 2QR, UK

SO Journal of Medicinal Chemistry (2002), 45(9), 1887-1900

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 137:196

AB A novel series of 3-heteroaryl-5,6-bis(aryl)-1-methyl-2-pyridones were developed with high affinity for the benzodiazepine (BZ) binding site of human  $\gamma$ -aminobutyric acid (GABAA) receptor ion channels, low binding selectivity for  $\alpha$ 2- and/or  $\alpha$ 3- over  $\alpha$ 1-containing GABAA receptor subtypes and high binding selectivity over  $\alpha$ 5 subtypes. High affinity appeared to be associated with a coplanar conformation of the pyridone and sulfur-containing 3-heteroaryl rings resulting from an attractive S...O intramol. interaction. Functional selectivity (i.e., selective efficacy) for  $\alpha$ 2 and/or  $\alpha$ 3 GABAA receptor subtypes over  $\alpha$ 1 was observed in several of these compds. in electrophysiolog. assays. Furthermore, an  $\alpha$ 3 subtype selective inverse agonist was pro-convulsant and anxiogenic in rodents while an  $\alpha$ 2/ $\alpha$ 3 subtype selective partial agonist was anticonvulsant and anxiolytic, supporting the hypothesis that subtype selective BZ site agonists may provide new anxiolytic therapies.


IT 433217-25-5P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(new class of 2-pyridone GABAA benzodiazepine site ligands with anxiolytic activity)

RN 433217-25-5 HCAPLUS

CN [2,4'-Bipyridin]-6(1H)-one, 3-(4-methoxyphenyl)-1-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)- (9CI) (CA INDEX NAME)



RETABLE

| Referenced Author<br>(RAU) | Year<br>(RPY) | VOL<br>(RVL) | PG<br>(RPG) | Referenced Work<br>(RWK) | Referenced<br>File |
|----------------------------|---------------|--------------|-------------|--------------------------|--------------------|
| Atack, J                   | 1999          | 20           | 255         | Neuropsychopharmacol     | HCAPLUS            |
| Bondi, A                   | 1964          | 68           | 441         | J Phys Chem              | HCAPLUS            |
| Broughton, H               |               |              |             | WO---9804559             | HCAPLUS            |
| Chebib, M                  | 2000          | 43           | 1427        | J Med Chem               | HCAPLUS            |
| Collins, I                 |               |              |             | US---6200982             | HCAPLUS            |
| Collins, I                 | 2000          | 10           | 1381        | Bioorg Med Chem Lett     | HCAPLUS            |
| Collins, I                 | 1999          | 40           | 4069        | Tetrahedron Lett         | HCAPLUS            |
| Creuven, I                 | 1996          | 26           | 777         | J Chem Crystallogr       | HCAPLUS            |
| Dawson, G                  | 2000          | 295          | 1051        | J Pharmacol Exp Ther     | HCAPLUS            |
| Doisy, X                   | 1999          | 7            | 921         | Bioorg Med Chem          | HCAPLUS            |
| Dondoni, A                 | 1984          | 25           | 3633        | Tetrahedron Lett         | HCAPLUS            |
| Hadingham, K               | 1993          | 43           | 970         | Mol Pharmacol            | HCAPLUS            |
| Hansell, D                 | 1996          | C52          | 136         | Acta Crystallogr         | HCAPLUS            |
| Huang, Q                   | 1999          | 16           | 55          | Drug Des Discovery       | HCAPLUS            |
| Huang, Q                   | 2000          | 43           | 71          | J Med Chem               | HCAPLUS            |
| Jacobsen, E                | 1999          | 42           | 1123        | J Med Chem               | HCAPLUS            |
| Jones, G                   | 1984          | 2            | 395         | Comprehensive Hetero     |                    |
| Jones, G                   | 1996          | 5            | 167         | Comprehensive Hetero     | HCAPLUS            |
| Knaus, G                   | 1974          | 39           | 1192        | J Org Chem               | HCAPLUS            |
| Korpi, E                   | 1997          | 29           | 275         | Ann Med                  | HCAPLUS            |
| Krapcho, A                 | 1973          |              | 957         | Tetrahedron Lett         | HCAPLUS            |
| Krogsgaard-Larsen, P       | 1997          | 5            | 355         | Eur J Pharm Sci          |                    |
| Liang, G                   | 1996          | 37           | 6627        | Tetrahedron Lett         | HCAPLUS            |
| Low, K                     | 2000          | 290          | 131         | Science                  | HCAPLUS            |
| Macleod, A                 | 1990          | 33           | 2052        | J Med Chem               | HCAPLUS            |
| Martin, G                  | 1992          | 57           | 5907        | J Org Chem               | HCAPLUS            |
| Martin, I                  | 1999          | 9            | 1347        | Exp Opin Ther Pat        | HCAPLUS            |
| Maurin, J                  | 1999          | 73           | 377         | Pol J Chem               | HCAPLUS            |
| McKernan, R                | 2000          | 3            | 587         | Nat Neurosci             | HCAPLUS            |
| McKernan, R                | 1996          | 19           | 139         | Trends Neurosci          | MEDLINE            |
| Mehta, A                   | 1999          | 29           | 196         | Brain Res Rev            | HCAPLUS            |
| Meth-Cohn, O               | 1984          |              | 1173        | J Chem Soc, Perkin T     | HCAPLUS            |
| Miyaura, N                 | 1981          | 11           | 513         | Synth Commun             | HCAPLUS            |
| Ogura, K                   | 1979          | 52           | 2013        | Bull Chem Soc Jpn        | HCAPLUS            |
| Pellow, S                  | 1986          | 24           | 525         | Pharmacol, Biochem B     | HCAPLUS            |
| Reynolds, D                | 2001          | 22           | 402         | Trends Pharmacol Sci     | HCAPLUS            |
| Robertson, D               | 1986          | 29           | 635         | J Med Chem               | HCAPLUS            |
| Rudolph, U                 | 1999          | 401          | 796         | Nature                   | HCAPLUS            |
| Rudolph, U                 | 2001          | 22           | 188         | Trends Pharmacol Sci     | HCAPLUS            |
| Sice, J                    | 1954          | 19           | 70          | J Org Chem               | HCAPLUS            |
| Sieghart, W                | 1999          | 34           | 379         | Neurochem Int            | HCAPLUS            |
| Sieghart, W                | 2000          | 21           | 411         | Trends Pharmacol Sci     | HCAPLUS            |
| Sigel, E                   | 1997          | 18           | 425         | Trends Pharmacol Sci     | HCAPLUS            |
| Sircar, I                  | 1987          | 30           | 1023        | J Med Chem               | HCAPLUS            |
| Stephenson, F              | 1995          | 310          | 1           | Biochem J                | HCAPLUS            |
| Tenbrink, R                | 1994          | 37           | 758         | J Med Chem               | HCAPLUS            |
| Teuber, L                  | 1999          | 5            | 317         | Curr Pharm Des           | HCAPLUS            |

|            |      |     |      |                    |         |
|------------|------|-----|------|--------------------|---------|
| Tully, W   | 1991 | 34  | 2060 | J Med Chem         | HCAPLUS |
| Wafford, K | 1993 | 43  | 240  | Mol Pharmacol      | HCAPLUS |
| Wang, Q    | 1999 | 5   | 125  | CNS Drug Rev       | HCAPLUS |
| Watjen, F  | 1989 | 32  | 2282 | J Med Chem         | HCAPLUS |
| Whiting, P | 1999 | 34  | 387  | Neurochem Int      | HCAPLUS |
| Wouters, J | 1997 | C53 | 892  | Acta Crystallogr   | HCAPLUS |
| Yu, S      | 1999 | 9   | 186  | Med Chem Res       | HCAPLUS |
| Zhang, W   | 1995 | 12  | 193  | Drug Des Discovery | HCAPLUS |

L28 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:319892 HCAPLUS

DN 134:326520

TI Preparation of naphthyridine derivatives as phosphodiesterase IV inhibitors

IN Iwata, Masahiro; Kawano, Noriyuki; Takuwa, Tomofumi; Shiraki, Ryota; Kobayashi, Miki; Takeuchi, Makoto

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 61 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

|      | PATENT NO.  | KIND       | DATE     | APPLICATION NO. | DATE         |
|------|---|------------|----------|-----------------|--------------|
| PI   | WO2001030779  | A1         | 20010503 | 2000WO-JP07433  | 20001024 <-- |
|      | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW<br>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG |            |          |                 |              |
|      | CA---2385178  | AA         | 20010503 | 2000CA-2385178  | 20001024 <-- |
|      | AU2000079560  | A5         | 20010508 | 2000AU-0079560  | 20001024 <-- |
|      | AU---779081   | B2         | 20050106 |                 |              |
|      | JP2001192385  | A2         | 20010717 | 2000JP-0323880  | 20001024 <-- |
|      | JP---3373838  | B2         | 20030204 |                 |              |
|      | BR2000014981  | A          | 20020716 | 2000BR-0014981  | 20001024 <-- |
|      | EP---1225173  | A1         | 20020724 | 2000EP-0970038  | 20001024 <-- |
|      | EP---1225173  | B1         | 20050928 |                 |              |
|      | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL   |            |          |                 |              |
|      | RU---2240322  | C2         | 20041120 | 2002RU-0111005  | 20001024 <-- |
|      | AT---305470   | E          | 20051015 | 2000AT-0970038  | 20001024 <-- |
|      | US---6740662  | B1         | 20040525 | 2002US-0111077  | 20020419 <-- |
| PRAI | 1999JP-0302544  | A          | 19991025 | <--             |              |
|      | 2000WO-JP07433  | W          | 20001024 | <--             |              |
| OS   | MARPAT  | 134:326520 |          |                 |              |
| GI   |   |            |          |                 |              |



AB The title compds. I [R1 = alkyl, etc.; R2 - R4 = H, alkyl, etc.; R5 = (un)substituted Ph, etc.; R6 = OH, NH2, etc.; X = bond, alkylene, etc.] are prepared I are useful as remedies for respiratory diseases related to


phosphodiesterase IV. Compds. of this invention in vitro showed IC<sub>50</sub> values of ≤ 11 nM against phosphodiesterase IV.

IT 337358-29-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of naphthyridine derivs. as phosphodiesterase IV inhibitors)

RN 337358-29-9 HCAPLUS

CN 1,8-Naphthyridin-2(1H)-one, 3-(2-amino-4-thiazolyl)-4-(3-chlorophenyl)-1-ethyl-7-methyl- (9CI) (CA INDEX NAME)




IT 337358-74-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of naphthyridine derivs. as phosphodiesterase IV inhibitors)

RN 337358-74-4 HCAPLUS

CN Acetamide, N-[4-[4-(3-chlorophenyl)-1-ethyl-1,2-dihydro-7-methyl-2-oxo-1,8-naphthyridin-3-yl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



#### RETABLE

| Referenced Author<br>(RAU) | Year<br>(R PY) | VOL<br>(R VL) | PG<br>(R PG) | Referenced Work<br>(RWK) | Referenced<br>File |
|----------------------------|----------------|---------------|--------------|--------------------------|--------------------|
| Green Cross Corp           | 1995           |               |              | JP--07010875 A           | HCAPLUS            |
| Matsuura, A                | 1994           | 17            | 498          | Biol Pharm Bull          | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | JP--09048780 A           | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | JP--10212288 A           | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | CN--1191536 A            | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | CN--1245500 A            | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | US---5843957 A           | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | US---5843957 A           | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | WO---9638445 A1          | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | AU---9657808 A1          | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | AU---9749688 A1          | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | WO---9823615 A1          | HCAPLUS            |
| Sumitomo Pharmaceutical    |                |               |              | AU---9925473 A1          | HCAPLUS            |
| Sumitomo Pharmaceutical    | 1998           |               |              | EP----842933 A1          | HCAPLUS            |
| Sumitomo Pharmaceutical    | 1999           |               |              | EP----947515 A1          | HCAPLUS            |

|                         |      |  |   |   |
|-------------------------|------|--|---|---|
| Sumitomo Pharmaceutical | 1999 |  | WO---9943659 A1<br>CN---1156455 A<br>US---5817670 A<br>HU-----76980 A<br>AU---9532656 A1<br>WO---9606843 A1<br>EP---779292 A1 | HCAPLUS<br>HCAPLUS<br>HCAPLUS<br>HCAPLUS<br>HCAPLUS<br>HCAPLUS<br>HCAPLUS |
| Yamanouchi Pharmaceutic |      |  |   |   |
| Yamanouchi Pharmaceutic | 1997 |  |   |   |

L28 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:396846 HCAPLUS

DN 129:115023

TI Ensembles of rings with a coumarin unit. 2. Spectral luminescent properties and spin-orbit coupling in molecules of 3-(2-R-thiazol-4-yl)- and 3-(4-R-thiazol-2-yl)coumarins

AU Doroshenko, A. O.; Posokhov, E. A.; Belokon, Ya. V.; Kovalenko, S. N.; Ivanov, V. V.; Ponomarev, O. A.

CS Kharkov State University, Kharkov, 310077, Ukraine

SO Chemistry of Heterocyclic Compounds (New York) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (1998), Volume Date 1997, 33(10), 1177-1184

CODEN: CHCCAL; ISSN: 0009-3122

PB Consultants Bureau

DT Journal

LA English

AB The luminescence was studied of 3-(2-R-thiazol-4-yl)coumarins (R = Me, CH<sub>2</sub>CN, Ar) and some isomeric 3-(4-R-thiazol-2-yl)coumarins (R = Ar) with substituents of different electronic types both in the coumarin and in the aryl moieties. Ests. were obtained of the rate consts. for primary photophys. processes: emission of fluorescence and nonradiative degradation of the electronic excitation energy. The matrix elements for the spin-orbit coupling operator, and based on these matrix elements the intersystem crossing rate consts., were calculated. Deterioration of the fluorescent properties of the studied thiazolyl derivs. of coumarin when π-conjugated moieties are introduced into the thiazole ring is determined by the enhancement of the spin-orbit interaction in a system of levels of the π, π-type.


IT 209974-99-2 209975-00-8

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)

(luminescence and spin-orbit coupling in)


RN 209974-99-2 HCAPLUS

CN 2(1H)-Quinolinone, 3-(2-phenyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 209975-00-8 HCAPLUS

CN 2(1H)-Quinolinone, 6-methoxy-3-(2-phenyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



## RETABLE

| Referenced Author<br>(RAU) | Year<br>(RPY) | VOL<br>(RVL) | PG<br>(RPG) | Referenced Work<br>(RWK) | Referenced File |
|----------------------------|---------------|--------------|-------------|--------------------------|-----------------|
|----------------------------|---------------|--------------|-------------|--------------------------|-----------------|

|                |      |     |      |                        |         |
|----------------|------|-----|------|------------------------|---------|
| Asimov, M      | 1988 | 149 | 140  | Chem Phys Lett         | HCAPLUS |
| Asimov, M      | 1994 | 70  | 384  | Inst Fiz Akad Nauk B   |         |
| Asimov, M      | 1991 | 44  |      | Opt Spektrosk          | HCAPLUS |
| Asimov, M      | 1992 | 17  |      | Vestsi AN Belarusi     |         |
| Babich, E      | 1990 | 52  | 48   | Teor Eksp Khim         | HCAPLUS |
| Basharin, S    | 1990 | 3   | 211  | Zh Prikl Spektrosk     |         |
| Griffits, J    | 1982 | 76  | 211  | Dyes and Pigments      |         |
| Kovalenko, S   | 1995 | 76  | 189  | Kazan Med Zh           |         |
| McGlynn, S     | 1972 |     |      | Molecular Spectroscopy |         |
| Melhuish, W    | 1961 | 65  | 229  | J Phys Chem            | HCAPLUS |
| Minkin, V      | 1973 | 8   | 249  | Int J Sulfur Chem      |         |
| Muldakmetov, Z | 1983 |     |      | Optical and Magnetic   |         |
| Ponomarev, O   | 1989 | 8   | 1369 | Khim Fiz               | HCAPLUS |
| Ponomarev, O   | 1991 | 65  | 1846 | Zh Fiz Khim            | HCAPLUS |
| Sprague, J     | 1987 | 8   | 581  | J Comp Chem            | HCAPLUS |
| Ware, W        | 1973 | 77  | 2038 | J Phys Chem            | HCAPLUS |
| Ya, V          | 1997 |     | 1345 | Khim Geterotsikl Soe   |         |
| Yu, F          | 1990 | 69  | 313  | Opt Spektrosk          |         |
| Yu, F          | 1990 | 69  | 550  | Opt Spektrosk          |         |

L28 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:191726 HCAPLUS

DN 118:191726

TI Preparation oxazole and thiazole derivatives as active oxygen inhibitors

IN Chihiro, Masatoshi; Komatsu, Hajime; Tominaga, Michiaki; Yabuuchi, Youichi

PA Otsuka Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 560 pp.

CODEN: PIXXD2

DT Patent

LA Japanese


FAN.CNT 1

|      | PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE         |
|------|--|------|----------|-----------------|--------------|
| PI   | WO---9209586   | A1   | 19920611 | 1991WO-JP01659  | 19911129 <-- |
|      | W: AU, CA, KR, US                                      |      |          |                 |              |
|      | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE |      |          |                 |              |
|      | CA---2074933   | AA   | 19920531 | 1991CA-2074933  | 19911129 <-- |
|      | CA---2074933   | C    | 20021203 |                 |              |
|      | AU---9189367   | A1   | 19920625 | 1991AU-0089367  | 19911129 <-- |
|      | AU---656930  | B2   | 19950223 |                 |              |
|      | CA---2547947   | AA   | 19920625 | 1991CA-2547947  | 19911129 <-- |
|      | EP---513387  | A1   | 19921119 | 1991EP-0920815  | 19911129 <-- |
|      | EP---513387  | B1   | 20000301 |                 |              |
|      | R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE              |      |          |                 |              |
|      | JP---05051318  | A2   | 19930302 | 1991JP-0342495  | 19911129 <-- |
|      | EP---934937  | A1   | 19990811 | 1999EP-0107493  | 19911129 <-- |
|      | EP---934937  | B1   | 20020227 |                 |              |
|      | R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE              |      |          |                 |              |
|      | ES---2144403   | T3   | 20000616 | 1991ES-0920815  | 19911129 <-- |
|      | EP---1130017   | A2   | 20010905 | 2001EP-0112988  | 19911129 <-- |
|      | EP---1130017   | A3   | 20010919 |                 |              |
|      | EP---1130017   | B1   | 20050615 |                 |              |
|      | R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE              |      |          |                 |              |
|      | ES---2173683   | T3   | 20021016 | 1999ES-0107493  | 19911129 <-- |
|      | ES---2245660   | T3   | 20060116 | 2001ES-0112988  | 19911129 <-- |
|      | US---5643932   | A    | 19970701 | 1995US-0444728  | 19950519 <-- |
|      | US---5677319   | A    | 19971014 | 1995US-0482657  | 19950607 <-- |
|      | US---6080764   | A    | 20000627 | 1997US-0826343  | 19970325 <-- |
|      | JP---10101562  | A2   | 19980421 | 1997JP-0233370  | 19970813 <-- |
|      | JP---3182556   | B2   | 20010703 |                 |              |
|      | HK---1003938   | A1   | 20000721 | 1998HK-0103139  | 19980416 <-- |
|      | US----37556  | E    | 20020219 | 1999US-0245914  | 19990208 <-- |
| PRAI | 1990JP-0337727   | A    | 19901130 | <--             |              |
|      | 1991CA-2396738   | A3   | 19911129 | <--             |              |
|      | 1991EP-0920815   | A3   | 19911129 | <--             |              |

|                |    |          |     |
|----------------|----|----------|-----|
| 1999EP-0107493 | A3 | 19911129 | <-- |
| 1991JP-0342495 | A3 | 19911129 | <-- |
| 1991WO-JP01659 | A  | 19911129 | <-- |
| 1992US-0916082 | B1 | 19920729 | <-- |
| 1995US-0444728 | A3 | 19950519 | <-- |
| 1995US-0482657 | A3 | 19950607 | <-- |

OS MARPAT 118:191726

GI




AB The title compds. [I; R1 = (substituted) Ph; R2 = H, halo, alkyl, Ph alkoxy carbonyl, alkylamino, etc.; R3 = Q (wherein R = OH, CO<sub>2</sub>H, alkyl, alkenyl; m = 0-2); X = S, O], useful in treating thrombosis, arteriosclerosis, peptic ulcers, etc., are prepared. A suspension of 367 mg II and 430 mg 3,4-(MeO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CSNH<sub>2</sub> in EtOH was refluxed to give 160 mg thiazole salt III, which showed IC<sub>50</sub> of 1 μM against superoxide formation. I were also effective in treating arrhythmia, ischemic renal disorders, and myocardial necrosis.

IT 145737-12-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as active oxygen inhibitor)

RN 145737-12-8 HCPLUS

CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L28 ANSWER 10 OF 10 HCPLUS COPYRIGHT 2006 ACS on STN

AN 1991:143103 HCPLUS

DN 114:143103

TI 2-oxo-3-cyanobenzo[h]quinoline. Part II. Some reactions on 3-methyl ketone derivative

AU Michael, J.; Nabih, I.; El-Zahar, M.

CS Lab. Med. Chem., Natl. Res. Cent., Cairo, Egypt

SO Egyptian Journal of Chemistry (1990), Volume Date 1988, 31(1), 117-24


CODEN: EGJCA3; ISSN: 0367-0422

DT Journal

LA English

OS CASREACT 114:143103

GI




**AB** Bromination of RCOMe (R = Q throughout) by Br<sub>2</sub>-AcOH gave 86% RCOCH<sub>2</sub>Br (I) which was treated with KSCN to give 50% RCOCH<sub>2</sub>SCN followed by intramol. cycloaddn. to give 47% thiazole II (R<sub>1</sub> = OH). Addnl. obtained were II (R<sub>1</sub> = NH<sub>2</sub>, Me) from I and H<sub>2</sub>NCSNH<sub>2</sub> and MeCSNH<sub>2</sub>, resp. Oxidation of I by SeO<sub>2</sub>-EtOH and SeO<sub>2</sub>-dioxane gave 75 and 79% RCOCO<sub>2</sub>Et and RCOCHO, resp. which were cyclocondensed with o-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> to give 53% quinoxaline III and 52% quinoxaline IV, resp. Addnl. obtained were 52-84% benzoquinolines V (X = O, R<sub>2</sub> = Me<sub>2</sub>CH, Bu, Ph; X = S, R<sub>2</sub> = Me, Ph) and 68% benzopyranoquinolinone VI.

**IT** 132894-68-9P 132894-69-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


**RN** 132894-68-9 HCPLUS

**CN** Benzo[h]quinolin-2(1H)-one, 3-(2-amino-4-thiazolyl)-5,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)



**RN** 132894-69-0 HCPLUS

**CN** Benzo[h]quinolin-2(1H)-one, 5,6-dihydro-3-(2-methyl-4-thiazolyl)-4-phenyl- (9CI) (CA INDEX NAME)



=> b uspatall  
FILE 'USPATFULL' ENTERED AT 09:24:52 ON 15 AUG 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:24:52 ON 15 AUG 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitstr hitrn 132 3-4

L32 ANSWER 3 OF 10 USPATFULL on STN

AN 2004:294735 USPATFULL

TI Compounds and methods of uses

IN Norman, Mark H., Thousand Oaks, CA, United States  
Wang, Hui-Ling, Thousand Oaks, CA, United States  
Rzasa, Robert, Ventura, CA, United States  
Zhong, Wenge, Thousand Oaks, CA, United States  
Nguyen, Thomas, Thousand Oaks, CA, United States  
Kaller, Matthew, Ventura, CA, United States  
Liu, Hu, Brooklyn, NY, United States

PA Amgen, Inc., Thousand Oaks, CA, United States (U.S. corporation)

PI US---6822097 B1 20041123

AI 2003US-0360226 20030206 (10)

PRAI 2002US-355313P 20020207 (60)

<--

DT Utility

FS GRANTED

EXNAM Primary Examiner: Seaman, D. Margaret

CLMN Number of Claims: 44

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 15475

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 578017-64-8P

(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

RN 578017-64-8 USPATFULL

CN 5-Quinolincarboxylic acid, 1,2-dihydro-2-oxo-3-[2-(4-pyridinyl)-4-thiazolyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 578017-64-8P 578017-68-2P 578017-70-6P  
 578017-96-6P 578018-16-3P 578018-20-9P  
 578018-25-4P 578018-29-8P 578018-34-5P  
 578018-44-7P 578018-57-2P 578018-62-9P  
 578018-82-3P 578018-85-6P 578018-94-7P  
 (preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

IT 209974-99-2P 578017-57-9P 578017-58-0P  
 578017-59-1P 578017-60-4P 578017-61-5P  
 578017-62-6P 578017-63-7P 578017-65-9P  
 578017-66-0P 578017-67-1P 578017-69-3P  
 578017-71-7P 578017-72-8P 578017-73-9P  
 578017-74-0P 578017-75-1P 578017-76-2P  
 578017-77-3P 578017-78-4P 578017-79-5P  
 578017-80-8P 578017-81-9P 578017-82-0P  
 578017-83-1P 578017-84-2P 578017-85-3P  
 578017-87-5P 578017-89-7P 578017-90-0P  
 578017-92-2P 578017-94-4P 578017-95-5P  
 578017-97-7P 578017-98-8P 578017-99-9P  
 578018-00-5P 578018-01-6P 578018-02-7P  
 578018-03-8P 578018-04-9P 578018-05-0P  
 578018-06-1P 578018-07-2P 578018-08-3P  
 578018-09-4P 578018-10-7P 578018-11-8P  
 578018-12-9P 578018-13-0P 578018-14-1P  
 578018-15-2P 578018-17-4P 578018-18-5P  
 578018-19-6P 578018-21-0P 578018-22-1P  
 578018-23-2P 578018-24-3P 578018-26-5P  
 578018-27-6P 578018-28-7P 578018-30-1P  
 578018-31-2P 578018-32-3P 578018-33-4P  
 578018-35-6P 578018-36-7P 578018-37-8P  
 578018-38-9P 578018-39-0P 578018-40-3P  
 578018-41-4P 578018-42-5P 578018-43-6P  
 578018-45-8P 578018-46-9P 578018-47-0P  
 578018-48-1P 578018-49-2P 578018-50-5P  
 578018-51-6P 578018-52-7P 578018-53-8P  
 578018-54-9P 578018-55-0P 578018-56-1P  
 578018-58-3P 578018-59-4P 578018-60-7P  
 578018-61-8P 578018-63-0P 578018-64-1P  
 578018-65-2P 578018-66-3P 578018-67-4P  
 578018-68-5P 578018-69-6P 578018-76-5P  
 578018-77-6P 578018-78-7P 578018-79-8P  
 578018-80-1P 578018-81-2P 578018-83-4P  
 578018-84-5P 578018-86-7P 578018-87-8P  
 578018-88-9P 578018-89-0P 578018-90-3P  
 578018-91-4P 578018-92-5P 578018-93-6P  
 578018-95-8P 578018-96-9P 578018-97-0P  
 578018-98-1P 578018-99-2P 578019-00-8P  
 578019-01-9P 578019-02-0P 578019-03-1P  
 578019-04-2P 578019-05-3P 578019-06-4P  
 578019-07-5P 578019-08-6P 578019-09-7P  
 578019-10-0P 578019-11-1P 578019-12-2P  
 578019-13-3P 578019-14-4P 578019-15-5P  
 578019-16-6P 578019-17-7P 578019-18-8P  
 578019-19-9P 578019-20-2P 578019-21-3P  
 578019-22-4P 578019-23-5P 578019-24-6P

578019-25-7P 578019-26-8P 578019-27-9P  
 578019-28-0P 578019-29-1P 578019-30-4P  
 578019-31-5P 578019-32-6P 578019-33-7P  
 578019-34-8P 578019-35-9P 578019-36-0P  
 578019-37-1P 578019-38-2P 578019-39-3P  
 578019-40-6P 578019-41-7P 578019-42-8P  
 578019-43-9P 578019-44-0P 578019-45-1P  
 578019-46-2P 578019-47-3P 578019-48-4P  
 578019-49-5P 578019-50-8P 578019-51-9P  
 578019-52-0P 578019-53-1P 578019-54-2P  
 578019-55-3P 578019-56-4P 578019-57-5P  
 578019-58-6P 578019-59-7P 578019-60-0P  
 578020-21-0P 578020-22-1P 578020-24-3P  
 578020-26-5P 578020-27-6P 578020-28-7P

(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

IT 578020-18-5 578020-20-9  
 (preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)  
 IT 578020-04-9P 578020-08-3P 578020-09-4P  
 578020-11-8P 578020-12-9P 578020-13-0P  
 578020-14-1P 578020-15-2P  
 (preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

L32 ANSWER 4 OF 10 USPATFULL on STN

AN 2004:190788 USPATFULL

TI Pyrid-2-one derivatives and methods of use

IN Zhong, Wenge, Thousand Oaks, CA, UNITED STATES

Norman, Mark Henry, Thousand Oaks, CA, UNITED STATES

Kaller, Matthew, Ventura, CA, UNITED STATES

Nguyen, Thomas, Thousand Oaks, CA, UNITED STATES

Rzasa, Robert Michael, Ventura, CA, UNITED STATES

Tegley, Christopher, Thousand Oaks, CA, UNITED STATES

Wang, Hui-Ling, Thousand Oaks, CA, UNITED STATES

PI US2004147561 A1 20040729

AI 2003US-0736289 A1 20031212 (10)

PRAI 2002US-436787P 20021227 (60)

<--

DT Utility

FS APPLICATION

LREP AMGEN INC., U.S. Patent Operations/JWB, Dept. 4300, M/S 27-4-A, One Amgen Center Drive, Thousand Oaks, CA, 91320-1799

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 7376

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 727383-80-4P, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid trifluoroacetate  
 (Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

RN 727383-80-4 USPATFULL

CN 3-Pyridinecarboxylic acid, 1,6-dihydro-2-methyl-6-oxo-5-[2-(4-pyridinyl)-4-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 727383-79-1  
CMF C15 H11 N3 O3 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



- IT 727383-80-4P, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid trifluoroacetate  
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)
- IT 727382-46-9P, Ethyl 2-ethyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydropyridine 3-carboxylate 727382-58-3P, Ethyl 2-isopropyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-61-8P, Ethyl 2-isopropyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-78-7P 727383-04-2P, Ethyl 5-[2-(2-chloro-4-pyridinyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-27-9P, Ethyl 5-[2-(2-(4-Methoxybenzylamino)pyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-30-4P, Ethyl 2-methyl-5-[2-(methylamino)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-52-0P, 2-(Isopropyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylic acid 727383-77-9P, 1,1-Dimethylethyl 2-methyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-89-3P, 5-Hydroxymethyl-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-52-3P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-hydroxyethyl)amide 727384-54-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-hydroxypropyl)amide 727384-61-4P, 2-(2-Benzylxyethyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester 727384-65-8P, 2-(2-Hydroxyethyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester  
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)
- IT 727382-48-1P 727382-49-2P, Ethyl 2-ethyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-50-5P, Ethyl 2-ethyl-6-oxo-5-[2-(benzodioxol-5-yl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-51-6P, Ethyl 6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate 727382-53-8P, Ethyl 2-trifluoromethyl-6-oxo-5-[2-(3-chloro-4-

pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727382-55-0P, Ethyl 6-oxo-5-[2-[(2-pyridylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate  
 727382-56-1P, Ethyl 6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate  
 727382-57-2P, Ethyl 2-trifluoromethyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-60-7P,  
 Ethyl 2-isopropyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-62-9P, Ethyl  
 2-propyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-65-2P, Ethyl 2-propyl-6-oxo-5-[2-  
 [(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-66-3P, Ethyl 2-propyl-6-oxo-5-[2-[(2-  
 thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-67-4P, Ethyl 6-oxo-2-  
 [(phenylmethoxy)methyl]-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-71-0P, Ethyl 6-oxo-2-  
 [(phenylmethoxy)methyl]-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-72-1P  
 727382-74-3P, 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]-1,7,8-trihydro-5H-pyrano[4,3-b]pyridin-2-one 727382-76-5P  
 727382-79-8P, 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]-1,5,6,7,8-pentahydropyridino[3,2-c]pyridin-2-one dihydrochloride  
 727382-80-1P, Ethyl 2-[(4-methoxyphenyl)methoxy]methyl]-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727382-85-6P, Ethyl 2-methyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-89-0P, Ethyl 5-[2-[[[(4-fluorophenyl)methyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727382-90-3P, Ethyl  
 2-methyl-6-oxo-5-[2-(2-thienyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-92-5P, Ethyl 2-methyl-6-oxo-5-[2-(phenylthiomethyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727382-93-6P, Ethyl 5-[2-(2-ethyl-4-pyridinyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727382-94-7P,  
 Ethyl 2-methyl-6-oxo-5-[2-[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727382-95-8P, Ethyl 2-methyl-6-oxo-5-[2-(3-thienyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-96-9P, Ethyl  
 5-[2-(2H-benzo[d]-1,3-dioxolan-5-yl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727382-97-0P, Ethyl  
 2-methyl-6-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate 727382-98-1P, Ethyl 2-methyl-6-oxo-5-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727382-99-2P, Ethyl 5-[2-(2,6-dichlorophenyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-00-8P,  
 Ethyl 2-methyl-5-[2-(2-methyl-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-01-9P, Ethyl  
 5-[2-[[furan-2-ylmethyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-02-0P, Ethyl  
 5-[2-[[tert-butyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-03-1P, Ethyl  
 2-methyl-6-oxo-5-[2-(3-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-06-4P, Ethyl 2-methyl-6-oxo-5-[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727383-07-5P, Ethyl 5-[2-(3,5-dichloropyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-08-6P,  
 Ethyl 5-[2-[(methylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-09-7P, Ethyl  
 5-[2-[3-[(4-chlorophenyl)sulfonyl]methyl]-2-thienyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-10-0P,  
 Ethyl 2-methyl-6-oxo-5-[2-[2-(1-piperidinyl)-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-11-1P, Ethyl  
 2-methyl-5-[2-[2-[(2-methylpropyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-12-2P, Ethyl  
 2-methyl-6-oxo-5-[2-[(3-pyridinylmethyl)amino]-4-pyridinyl]-1,3-

thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-13-3P,  
 Ethyl 2-methyl-6-oxo-5-[2-[2-[(phenylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-14-4P,  
 Ethyl 2-methyl-6-oxo-5-[2-[2-oxo-3-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-15-5P, Ethyl 5-[2-[2-[(diethylamino)ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-16-6P, Ethyl 5-[2-[2-[(fur-2-ylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-17-7P, Ethyl 5-[2-[2-[(2-(thien-2-yl)ethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-18-8P, Ethyl 5-[2-[2-(4-fluorobenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-19-9P, Ethyl 5-[2-(2-butylaminopyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-20-2P, Ethyl 5-[2-[2-[(carbamoylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-21-3P, Ethyl 5-[2-[2-(acetylamino)ethylamino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-22-4P, N-[2-[(4-[(6-Methyl-2-oxo-1,2-dihydropyridin-3-yl)-1,3-thiazol-2-yl]pyridin-2-yl)amino]ethyl]acetamide 727383-23-5P, N-(Cyclopropylmethyl)-5-[2-[2-[(cyclopropylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide hydrochloride 727383-24-6P, Ethyl 5-[2-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-25-7P, Ethyl 5-[2-[2-[(Cyclopentylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-26-8P, 5-[2-[2-[(4-Methoxybenzyl)amino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(4-methoxybenzyl)amide hydrochloride 727383-28-0P, Ethyl 2-methyl-6-oxo-5-[2-[(amino)-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-29-1P 727383-31-5P, Ethyl 2-methyl-5-[2-[methyl(phenylsulfonyl)amino]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-32-6P 727383-33-7P, Ethyl 2-methyl-5-[2-[methyl(phenylsulfonyl)amino]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride (1/2) 727383-34-8P, 5-[(Phenylmethyl)oxy]-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-35-9P, 6-(Methoxymethyl)-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-37-1P, 5-Phenoxy-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-38-2P, 5-Phenoxy-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone hydrochloride (1/3) 727383-39-3P, 6-Methyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-40-6P, Ethyl 2-(1-methylethyl)-5-[2-(2-methoxy-4-pyridinyl)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-42-8P, Ethyl 2-methyl-5-[2-[2-(methoxy)-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-43-9P, Ethyl 2-methyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-44-0P, Ethyl 2-methyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-45-1P, Ethyl 2-methyl-6-oxo-5-[2-[(2-pyridylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-46-2P, Ethyl 2-methyl-5-[2-[1-methyl-1-(phenylsulfonyl)ethyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-47-3P, Ethyl 2-cyclopropyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-51-9P, Ethyl 2-cyclopropyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-53-1P, 5-Bromo-6-methyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-56-4P, Ethyl 2-methyl-5-[2-[(methylamino)-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-58-6P, 5-Amino-6-ethyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone

727383-65-5P, N-[2-Ethyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]acetamide 727383-66-6P,  
 4-Dimethylamino-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-68-8P, 6-Methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one 727383-69-9P,  
 2-Methyl-6-oxo-N-(2-pyridinylmethyl)-5-[2-[2-[(2-pyridinyl)methyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxamide  
 727383-70-2P, 6-Methyl-3-[2-[2-[(2-pyridinylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-71-3P,  
 Ethyl 2-methyl-6-oxo-5-[2-[2-(2-pyridinylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-72-4P,  
 Ethyl 2-methyl-6-oxo-5-[2-[2-[(2-phenyloxy)ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-73-5P,  
 5-[2-[2-(Ethoxy)-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylic acid 727383-75-7P, Ethyl  
 5-[2-(2-dimethylaminopyridin-4-yl)-1,3-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-76-8P, Ethyl  
 5-[2-(2-methylaminopyridin-4-yl)-1,3-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-79-1P,  
 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 727383-81-5P, 6-Methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-82-6P, 2-(Pyrrolidin-1-yl)ethyl  
 2-methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylate 727383-84-8P, 2-(Pyrrolidin-1-yl)ethyl  
 2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylate 727383-85-9P, 6-Ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-86-0P,  
 6-Isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one  
 727383-87-1P, 3-(Diethylamino)propyl 2-ethyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727383-88-2P, 3-(Diethylamino)propyl 2-(1-methylethyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727383-91-7P, 5-[(3,6-Dihydro-2H-pyridin-1-yl)methyl]-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-94-0P  
 , 6-Ethyl-5-[(piperidin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one hydrochloride 727383-96-2P,  
 6-Ethyl-5-(4-methylpiperazin-1-ylmethyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one hydrochloride 727383-98-4P,  
 6-Ethyl-5-isobutylamino-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-01-2P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridin-3-yl]isobutyramide 727384-03-4P  
 , 6-Isopropyl-5-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-06-7P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-6-isopropyl-5-methyl-1H-pyridin-2-one 727384-08-9P,  
 6-Ethyl-5-propionyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-10-3P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-6-ethyl-5-propionyl-1H-pyridin-2-one 727384-11-4P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-dimethylaminoethyl ester  
 727384-13-6P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(pyrrolidin-1-yl)ethyl ester  
 727384-14-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-(2-oxopyrrolidin-1-yl)ethyl ester 727384-15-8P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-diisopropylaminoethyl ester 727384-16-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 2-diethylaminoethyl ester 727384-17-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 1-methylpyrrolidin-3-yl ester 727384-18-1P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 1-ethylpyrrolidin-3-yl ester  
 727384-19-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridine-3-carboxylic acid 1-ethylpiperidin-3-yl ester  
 727384-20-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-

yl]-1,6-dihydropyridine-3-carboxylic acid piperidin-4-ylmethyl ester  
 727384-22-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid 2-(1-methylpyrrolidin-2-  
 yl)ethyl ester 727384-23-8P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-  
 yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid  
 1-methylpiperidin-3-yl ester 727384-24-9P, 2-Isopropyl-6-oxo-5-  
 [2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid  
 2-dimethylamino-1-methylethyl ester 727384-25-0P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-  
 dihydropyridine-3-carboxylic acid 2-diethylamino-1-methylethyl ester  
 727384-26-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid 2-[(benzyl)(methyl)amino]ethyl  
 ester 727384-27-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-  
 thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-methylpiperidin-4-  
 yl ester 727384-28-3P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-  
 1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid  
 2-(piperazin-1-yl)ethyl ester 727384-29-4P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-  
 dihydropyridine-3-carboxylic acid 2-(2-oxopyrrolidin-1-yl)propyl ester  
 727384-30-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid phenethyl ester  
 727384-32-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid 2-(thiophen-2-yl)ethyl ester  
 727384-33-0P, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-  
 isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-diethylaminoethyl  
 ester 727384-36-3P, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-  
 isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid  
 2-diethylamino-1-methylethyl ester 727384-37-4P,  
 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-  
 dihydropyridine-3-carboxylic acid 2-diethylaminopropyl ester  
 727384-38-5P, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-  
 isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid  
 2-(1-methylpyrrolidin-2-yl)ethyl ester 727384-39-6P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-  
 dihydropyridine-3-carboxylic acid 2-(morpholin-4-yl)ethyl ester  
 727384-40-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid 2-(piperidin-1-yl)ethyl ester  
 727384-41-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid methyl ester  
 727384-42-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid methyl ester trifluoroacetate  
 727384-43-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid propyl ester  
 727384-44-3P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid propyl ester trifluoroacetate  
 727384-45-4P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid butyl ester  
 727384-46-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid butyl ester trifluoroacetate  
 727384-47-6P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid isobutyl ester  
 727384-48-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-  
 yl]-1,6-dihydropyridine-3-carboxylic acid isobutyl ester trifluoroacetate .  
 727384-49-8P  
 , 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-  
 carboxylic acid sec-butyl ester 727384-50-1P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-  
 dihydropyridine-3-carboxylic acid sec-butyl ester trifluoroacetate  
 727384-55-6P, 5-(4,5-Dihydrooxazol-2-yl)-6-isopropyl-3-[2-  
 (pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-56-7P,  
 6-Isopropyl-5-(5-methyl-4,5-dihydrooxazol-2-yl)-3-[2-(pyridin-4-yl)-1,3-  
 thiazol-4-yl]-1H-pyridin-2-one 727384-57-8P,  
 5-[(2-Dimethylaminoethyl)(ethyl)amino]methyl]-6-ethyl-3-[2-(pyridin-4-  
 yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-59-0P,  
 5-[(2-Diethylaminoethyl)(methyl)amino]methyl]-6-ethyl-3-[2-(pyridin-4-  
 yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-66-9P,

6-Oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-2-[2-(pyrrolidin-1-yl)ethyl]-1,6-dihdropyridine-3-carboxylic acid ethyl ester 727384-68-1P,  
 2-Isopropyl-N-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxamide 727384-69-2P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid amide 727384-70-5P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid isobutylamide 727384-72-7P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid methylamide 727384-73-8P,  
 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid (2-isopropylaminoethyl)amide  
727384-74-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid dimethylamide  
727384-75-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid N-(pyridin-4-ylmethyl)amide  
727384-76-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid N-(pyridin-2-ylmethyl)amide  
727384-78-3P, 5-(Furan-2-yl)-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-83-0P,  
 N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-2-methylaminoacetamide 727384-84-1P, 2-Dimethylamino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]acetamide 727384-85-2P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-3-(piperidin-1-yl)propionamide  
727384-86-3P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-3-methylbutyramide 727384-87-4P,  
 2-Amino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]acetamide 727384-88-5P,  
 2-tert-Butylamino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]acetamide 727384-89-6P,  
 (S)-2-Amino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-3-methylbutyramide 727384-90-9P,  
 N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-2-(piperidin-1-yl)acetamide 727384-92-1P,  
 N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihdropyridin-3-yl]-4-(piperidin-1-yl)butyramide 727384-93-2P,  
 5-(1,1-Dioxidoisothiazolidin-2-yl)-6-ethyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727384-94-3P, 6-Ethyl-5-(3-methylbutylamino)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one  
727384-95-4P, Ethyl 5-[2-[2-[(fur-2-ylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylate  
727384-96-5P, Ethyl 5-[2-[2-[(thien-2-yl)ethyl]amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylate  
727384-97-6P, Ethyl 5-[2-[2-(2-butylaminopyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylate 727384-98-7P,  
 Ethyl 5-[2-[2-[(carbamoylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylate 727384-99-8P, Ethyl  
 5-[2-(2-acetylaminooethylamino)pyridin-4-yl-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylate 727385-00-4P,  
 5-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylic acid N-(cyclopropylmethyl)amide  
727385-02-6P, Ethyl 5-[2-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylate  
727385-03-7P, Ethyl 5-[2-[(cyclopentylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylate  
727385-04-8P, 5-[2-[(4-methoxybenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihdropyridine-3-carboxylic acid  
 4-methoxybenzylamide 727385-06-0P, Ethyl 5-[2-(2-methylaminopyridin-4-yl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihdropyridine-3-carboxylate 727385-07-1P, Ethyl  
 2-methyl-5-[2-[(1-methylethyl)amino]ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihdropyridine-3-carboxylate  
727385-08-2P, Ethyl 2-isopropyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate hydrobromide (3/5)  
 (Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase

inhibitors for treatment of cell proliferation-related disorders)

IT 727383-61-1P, Ethyl 2-ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate  
 727383-62-2P, 2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylic acid  
 727383-63-3P, [2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]carbamic acid  
 tert-butyl ester 727383-64-4P, 5-Amino-6-ethyl-1-(4-methoxybenzyl)-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1H-pyridin-2-one  
 727383-90-6P, 5-[(Imidazol-1-yl)carbonyl]-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-92-8P,  
 6-Ethyl-5-hydroxymethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-93-9P,  
 6-Ethyl-1-(4-methoxybenzyl)-5-[(piperidin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-95-1P,  
 6-Ethyl-1-(4-methoxybenzyl)-5-[(4-methylpiperazin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-00-1P,  
 6-Ethyl-5-isobutylamino-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-02-3P,  
 N-[2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridin-3-yl]isobutyramide 727384-12-5P,  
 5-[(Imidazol-1-yl)carbonyl]-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-21-6P 727384-34-1P,  
 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylic acid 727384-35-2P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-5-[(imidazol-1-yl)carbonyl]-6-isopropyl-1H-pyridin-2-one 727384-58-9P, 5-[[2-Dimethylaminoethyl](ethyl)amino]methyl]-6-ethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-60-3P,  
 5-[[2-Dimethylaminoethyl](methyl)amino]methyl]-6-ethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one  
 (intermediate; preparation of quinazolines as Cdk2 and Cdk5 kinase  
 inhibitors for treatment of cell proliferation-related disorders)  
 IT 727383-74-6, 5-[2-(2-Chloropyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 727384-67-0  
 (preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for  
 treatment of cell proliferation-related disorders)

=> d bib abs hitstr l32 1-2 5-10

L32 ANSWER 1 OF 10 USPATFULL on STN  
 AN 2005:131933 USPATFULL  
 TI Imidazo[1,2-a]pyridine derivative  
 IN Takemura, Makoto, Edogawa-ku, JAPAN  
     Takahashi, Hisashi, Edogawa-ku, JAPAN  
     Kawakami, Katsuhiro, Edogawa-ku, JAPAN  
     Takeshita, Hiroshi, Edogawa-ku, JAPAN  
     Kimura, Youichi, Edogawa-ku, JAPAN  
     Watanabe, Jun, Edogawa-ku, JAPAN  
     Sugimoto, Yuichi, Edogawa-ku, JAPAN  
     Kitamura, Akihiro, Edogawa-ku, JAPAN  
     Nakajima, Ryohei, Edogawa-ku, JAPAN  
     Kanai, Kazuo, Edogawa-kun, JAPAN  
     Fujisawa, Tetsunori, Takaoka-shi, JAPAN  
 PI US2005113397 A1 20050526  
 AI 2003US-0502971 A1 20030130 (10)  
     2003WO-JP00912 20030130  
 PRAI 2002JP-0022767 20020131       <--  
 DT Utility  
 FS APPLICATION  
 LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800,  
     WASHINGTON, DC, 20037, US  
 CLMN Number of Claims: 10  
 ECL Exemplary Claim: 1  
 DRWN No Drawings

LN.CNT 9053

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the following formula (I), its salts or  
nsolvates thereof capable of specifically or selectively expressing an  
antifungal activity in a broad spectrum based on the novel mechanism  
thereof of 1,6- $\beta$ -glucan synthesis inhibition, and an antifungal  
agent containing any of them. ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 577776-44-4P 577776-48-8P 577776-51-3P


577777-06-1P

(preparation of imidazo[1,2-a]pyridine derivs. as antifungal agents with  
specific or selective 1,6- $\beta$ -glucan)


RN 577776-44-4 USPATFULL

CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 1,5-dihydro-3-methyl-2-(2-  
methyl-4-thiazolyl)-1-oxo- (9CI) (CA INDEX NAME)

RN 577776-48-8 USPATFULL


CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 2-(2-ethyl-4-thiazolyl)-1,5-  
dihydro-3-methyl-1-oxo- (9CI) (CA INDEX NAME)

RN 577776-51-3 USPATFULL

CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 1,5-dihydro-3-methyl-1-oxo-2-(2-  
phenyl-4-thiazolyl)- (9CI) (CA INDEX NAME)

RN 577777-06-1 USPATFULL

CN Dipyrido[1,2-a:2',3'-d]imidazole-9-carbonitrile, 1,6-dihydro-8-methyl-7-(2-  
methyl-4-thiazolyl)-6-oxo- (9CI) (CA INDEX NAME)



L32 ANSWER 2 OF 10 USPATFULL on STN

AN 2005:57357 USPATFULL

TI Quinolinone derivatives as inhibitors of c-fms kinase

IN Wall, Mark J., Harleysville, PA, UNITED STATES  
Player, Mark R., Phoenixville, PA, UNITED STATES  
Patch, Raymond Joseph, Yardley, PA, UNITED STATES  
Meegalla, Sanath, Boothwyn, PA, UNITED STATES  
Liu, Jian, Plainsboro, NJ, UNITED STATES  
Illig, Carl R., Phoenixville, PA, UNITED STATES  
Cheung, Wing, Plainsboro, NJ, UNITED STATES  
Chen, Jinsheng, Exton, PA, UNITED STATES  
Asgari, Davoud, Newtown, PA, UNITED STATES

PI US2005049274 A1 20050303

AI 2004US-0894940 A1 20040720 (10)

PRAI 2003US-488811P 20030722 (60)

DT Utility

FS APPLICATION

LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3251

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to compounds of Formulae I and II: ##STR1##

wherein R.<sup>1</sup>, R.<sup>2</sup>, R.<sup>3</sup>, R.<sup>5</sup>, R.<sup>6</sup>, Y.<sup>1</sup>, Y.<sup>2</sup>, Y.<sup>3</sup>, Y.<sup>4</sup> and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 835880-69-8P

(preparation of quinolinones as inhibitors of c-fms kinase)

RN 835880-69-8 USPATFULL

CN 6-Quinolinecarbonitrile, 4-(4-ethylphenyl)-1,2-dihydro-3-(2-methyl-4-thiazolyl)-2-oxo- (9CI) (CA INDEX NAME)




L32 ANSWER 5 OF 10 USPATFULL on STN


AN 2004:129634 USPATFULL  
 TI Naphthyridine derivatives  
 IN Iwata, Masahiro, Tsukuba, JAPAN  
     Kawano, Noriyuki, Tsukuba, JAPAN  
     Takuwa, Tomofumi, Tsukuba, JAPAN  
     Shiraki, Ryota, Tsukuba, JAPAN  
     Kobayashi, Miki, Tsukuba, JAPAN  
     Takeuchi, Makoto, Tsukui, JAPAN  
 PA Yamanouchi Pharmaceutical Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)  
 PI US---6740662 B1 20040525  
     WO2001030779 20010503 <--  
 AI 2002US-0111077 20020419 (10) <--  
     2000WO-JP07433 20001024 <--  
 PRAI 1999JP-0302544 19991025 <--  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Dentz, Bernard  
 LREP Sughrue Mion, PLLC  
 CLMN Number of Claims: 8  
 ECL Exemplary Claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT 2015  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB 2-Oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by bearing a specific substituent, --X--R.<sup>6</sup>, at the 3-position and a cyclic substituent, R.<sup>5</sup>, at the 4-position; or salts thereof. The derivatives and the salts are useful as drugs, particularly preventive or therapeutic agents for respiratory diseases related to PDE IV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 337358-29-9P  
     (preparation of naphthyridine derivs. as phosphodiesterase IV inhibitors)  
 RN 337358-29-9 USPATFULL  
 CN 1,8-Naphthyridin-2(1H)-one, 3-(2-amino-4-thiazolyl)-4-(3-chlorophenyl)-1-ethyl-7-methyl- (9CI) (CA INDEX NAME)



IT 337358-74-4P  
     (preparation of naphthyridine derivs. as phosphodiesterase IV inhibitors)  
 RN 337358-74-4 USPATFULL  
 CN Acetamide, N-[4-[4-(3-chlorophenyl)-1-ethyl-1,2-dihydro-7-methyl-2-oxo-1,8-naphthyridin-3-yl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 6 OF 10 USPATFULL on STN

AN 2003:79334 USPATFULL

TI Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production

IN Priepke, Henning, Warthausen, GERMANY, FEDERAL REPUBLIC OF Kauffmann-Hefner, Iris, Attenweiler, GERMANY, FEDERAL REPUBLIC OF Hauel, Norbert, Schemmerhofen, GERMANY, FEDERAL REPUBLIC OF Damm, Klaus, Biberach, GERMANY, FEDERAL REPUBLIC OF Schnapp, Andreas, Biberach, GERMANY, FEDERAL REPUBLIC OF

PA Boehringer Ingelheim Pharma KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PI US2003055263 A1 20030320

AI 2002US-0192456 A1 20020710 (10)

<--

PRAI DE 2001-10133665 20010711

<--

2001US-307449P 20010724 (60)

<--

DT Utility

FS APPLICATION

LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2028

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application relates to the use of the carboxylic acid derivatives of general formula

R.sub.1--A--B--R.sub.2 (I)

wherein

R.sub.1, R.sub.2, A and B are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, which have an inhibitory effect on telomerase, processes for the preparation thereof, pharmaceutical compositions containing these compounds and the use thereof as well as the preparation thereof.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 488816-08-6P

(drug candidate; preparation of thiazoles and related compds. as telomerase inhibitors)

RN 488816-08-6 USPATFULL

CN Benzoic acid, 2-[[[4-(1,2-dihydro-2-oxo-3-quinolinyl)-2-thiazolyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 7 OF 10 USPATFULL on STN

AN 2002:33452 USPATFULL

TI Superoxide radical inhibitor

IN Chihiro, Masatoshi, Naruto, JAPAN

Komatsu, Hajime, Tokyo, JAPAN

Tominaga, Michiaki, Itano-Gun, JAPAN

Yabuuchi, Yoichi, Tokushima, JAPAN

PA Otsuka Pharmaceutical Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)

PI US-----37556 E1 20020219 <--

US---5643932 19970701 (Original)

AI 1999US-0245914 19990208 (9) <--

1995US-0444728 19950519 (Original) <--

RLI Continuation of Ser. No. US 916082, now abandoned

PRAI 1990JP-0337727 19901130 <--

DT Reissue

FS GRANTED

EXNAM Primary Examiner: Gerstl, Robert

LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 6449

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1##

[wherein R.<sup>sup.1</sup> represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkyleneoxy group, or the like; R.<sup>sup.2</sup> represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxy carbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyryl group, or the like; R.<sup>sup.3</sup> represents a group of the formula, ##STR2##]

(R.<sup>sup.4B</sup> represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group, m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 145737-12-8P

(preparation of, as active oxygen inhibitor)

RN 145737-12-8 USPATFULL

CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA  
INDEX NAME)



L32 ANSWER 8 OF 10 USPATFULL on STN


AN 2000:80772 USPATFULL  
 TI Superoxide radical inhibitor  
 IN Chihiro, Masatoshi, Naruto, Japan  
     Komatsu, Hajime, Tokushima, Japan  
     Tominaga, Michiaki, Tokushima, Japan  
     Yabuuchi, Yoichi, Tokushima, Japan  
 PA Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
 PI US---6080764 20000627 <--  
 AI 1997US-0826343 19970325 (8) <--  
 RLI Division of Ser. No. 1995US-0482657, filed on 7 Jun 1995 which is a  
     division of Ser. No. 1995US-0444728, filed on 19 May 1995 which is a  
     continuation of Ser. No. US 916082  
 PRAI 1990JP-3377727 19901130 <--  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Gerstl, Robert  
 LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.  
 CLMN Number of Claims: 10  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 7154

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1## [wherein R.<sup>1</sup> represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkyleneoxy group, or the like; R.<sup>2</sup> represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxy carbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyryl group, or the like; R.<sup>3</sup> represents a group of the formula, ##STR2## (R.<sup>4</sup>B represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group. m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 145737-12-8P  
     (preparation of, as active oxygen inhibitor)  
 RN 145737-12-8 USPATFULL  
 CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA  
     INDEX NAME)



L32 ANSWER 9 OF 10 USPATFULL on STN

AN 97:94251 USPATFULL  
 TI Superoxide radical inhibitor  
 IN Chihiro, Masatoshi, Naruto, Japan  
     Komatsu, Hajime, Itano-gun, Japan  
     Tominaga, Michiaki, Itano-gun, Japan  
     Yabuuchi, Yoichi, Tokushima, Japan  
 PA Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)  
 PI US---5677319 19971014 <--  
 AI 1995US-0482657 19950607 (8) <--

RLI Division of Ser. No. 1995US-0444728, filed on 19 May 1995 which is a continuation of Ser. No. 1992US-0916082, filed on 29 Jul 1992, now abandoned

PRAI 1990JP-0337727 19901130 <--

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Finnegan, Henderson, Farabow, Garrett & Dunner

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 6751

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1## [wherein R.<sup>1</sup> represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkyleneoxy group, or the like; R.<sup>2</sup> represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxy carbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyryl group, or the like; R.<sup>3</sup> represents a group of the formula, ##STR2## (R.<sup>4</sup>)<sup>m</sup> represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group. m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.


CAS INDEXING IS AVAILABLE FOR THIS PATENT..

IT 145737-12-8P

(preparation of, as active oxygen inhibitor)

RN 145737-12-8 USPATFULL

CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 10 OF 10 USPATFULL on STN

AN 97:56698 USPATFULL

TI Superoxide radical inhibitor

IN Chihiro, Masatoshi, Naruto, Japan

Komatsu, Hajime, Itano-gun, Japan

Tominaga, Michiaki, Itano-gun, Japan

Yabuuchi, Yoichi, Tokushima, Japan

PA Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)

PI US---5643932 19970701 <--

AI 1995US-0444728 19950519 (8) <--

RLI Continuation of Ser. No. 1992US-0916082, filed on 29 Jul 1992, now abandoned

PRAI 1990JP-0337727 19901130 <--

DT Utility

FS Granted

EXNAM Primary Examiner: Gerstl, Robert

LREP Finnegan, Henderson, Farabow, Garrett & Dunner

CLMN Number of Claims: 11

ECL Exemplary Claim: 9

DRWN No Drawings

LN.CNT 6708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1## [wherein R.<sup>1</sup> represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkyleneoxy group, or the like; R.<sup>2</sup> represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxy carbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydro carbostyryl group, or the like; R.<sup>3</sup> represents a group of the formula, ##STR2## (R.<sup>4</sup> represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group. m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 145737-12-8P  
(preparation of, as active oxygen inhibitor)

RN 145737-12-8 USPATFULL

CN 2 (1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 08:52:57 ON 15 AUG 2006)

FILE 'HCAPLUS' ENTERED AT 08:59:25 ON 15 AUG 2006  
1 US2004147561/PN OR (US2003-736289 OR US2002-436787# OR US2006-3  
E ZHONG W/AU  
L2 302 E3-14  
E ZHONG WEN/AU  
L3 10 E3  
E ZHONG WENGE/AU  
L4 17 E3  
E NORMAN M/AU  
L5 39 E3,E10  
E NORMAN MARK/AU  
L6 85 E3,E7-8  
E KALLER M/AU  
L7 9 E4,E6-8  
E NGUYEN T/AU  
L8 1055 E3-60  
E RZASA R/AU  
L9 21 E4-7  
E RZASA B/AU  
L10 1 E3  
E TEGLEY C/AU  
L11 51 E4-7  
E WANG H/AU  
L12 1995 E3,E24  
E WANG HUI/AU  
L13 1715 E3,E52-54  
E WANG HUILING/AU  
L14 67 E2-3

E HUI N/AU  
E HUIING N/AU  
E HUILING N/AU  
E WENGE N/AU

FILE 'REGISTRY' ENTERED AT 09:07:36 ON 15 AUG 2006

FILE 'HCAPLUS' ENTERED AT 09:07:37 ON 15 AUG 2006  
L15 TRA L1 1- RN : 403 TERMS

FILE 'REGISTRY' ENTERED AT 09:07:37 ON 15 AUG 2006

L16 403 SEA L15  
L17 403 S L15  
L18 283 S L17 AND NC5/ES  
L19 211 L18 AND (NCSC2 OR NSCNC)/ES  
L20 STR  
L21 STR L20  
L22 26 L21  
L23 453 L21 FULL  
SAV TEM L23 DAV289FO/A  
L24 208 L23 AND L16

FILE 'HCAPLUS' ENTERED AT 09:18:38 ON 15 AUG 2006

L25 14 L23  
L26 2 L25 AND L1-14  
L27 12 L25 NOT L26  
L28 10 L27 AND (PY<=2002 OR AY<=2002 OR PRY<=2002)

FILE 'HCAOLD' ENTERED AT 09:19:16 ON 15 AUG 2006

L29 0 L23

FILE 'USPATFULL, USPAT2' ENTERED AT 09:19:24 ON 15 AUG 2006

L30 10 L23  
L31 9 L30 AND (PY<=2002 OR AY<=2002 OR PRY<=2002)  
L32 10 L30-31

=>